<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83628</article-id><article-id pub-id-type="doi">10.7554/eLife.83628</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Hierarchical sequence-affinity landscapes shape the evolution of breadth in an anti-influenza receptor binding site antibody</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-293362"><name><surname>Phillips</surname><given-names>Angela M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9806-7574</contrib-id><email>angela.phillips@ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-295784"><name><surname>Maurer</surname><given-names>Daniel P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2074-5416</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-295785"><name><surname>Brooks</surname><given-names>Caelan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-243887"><name><surname>Dupic</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-295787"><name><surname>Schmidt</surname><given-names>Aaron G</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-40694"><name><surname>Desai</surname><given-names>Michael M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9581-1150</contrib-id><email>mdesai@oeb.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Organismic and Evolutionary Biology, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Microbiology and Immunology, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/053r20n13</institution-id><institution>Ragon Institute of MGH, MIT, and Harvard</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Microbiology, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Physics, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>NSF-Simons Center for Mathematical and Statistical Analysis of Biology, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Quantitative Biology Initiative, Harvard University</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83628</elocation-id><history><date date-type="received" iso-8601-date="2022-09-21"><day>21</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-09"><day>09</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-21"><day>21</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.21.508900"/></event></pub-history><permissions><copyright-statement>© 2023, Phillips, Maurer et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Phillips, Maurer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83628-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83628-figures-v3.pdf"/><abstract><p>Broadly neutralizing antibodies (bnAbs) that neutralize diverse variants of a particular virus are of considerable therapeutic interest. Recent advances have enabled us to isolate and engineer these antibodies as therapeutics, but eliciting them through vaccination remains challenging, in part due to our limited understanding of how antibodies evolve breadth. Here, we analyze the landscape by which an anti-influenza receptor binding site (RBS) bnAb, CH65, evolved broad affinity to diverse H1 influenza strains. We do this by generating an antibody library of all possible evolutionary intermediates between the unmutated common ancestor (UCA) and the affinity-matured CH65 antibody and measure the affinity of each intermediate to three distinct H1 antigens. We find that affinity to each antigen requires a specific set of mutations – distributed across the variable light and heavy chains – that interact non-additively (i.e., epistatically). These sets of mutations form a hierarchical pattern across the antigens, with increasingly divergent antigens requiring additional epistatic mutations beyond those required to bind less divergent antigens. We investigate the underlying biochemical and structural basis for these hierarchical sets of epistatic mutations and find that epistasis between heavy chain mutations and a mutation in the light chain at the V<sub>H</sub>-V<sub>L</sub> interface is essential for binding a divergent H1. Collectively, this is the first work to comprehensively characterize epistasis between heavy and light chain mutations and shows that such interactions are both strong and widespread. Together with our previous study analyzing a different class of anti-influenza antibodies, our results implicate epistasis as a general feature of antibody sequence-affinity landscapes that can potentiate and constrain the evolution of breadth.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>antibody</kwd><kwd>influenza</kwd><kwd>epistasis</kwd><kwd>evolution</kwd><kwd>breadth</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>S. cerevisiae</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Hanna H. Gray Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Phillips</surname><given-names>Angela M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000854</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Dupic</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI146779</award-id><principal-award-recipient><name><surname>Schmidt</surname><given-names>Aaron G</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01AI89618-A1</award-id><principal-award-recipient><name><surname>Schmidt</surname><given-names>Aaron G</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1764269</award-id><principal-award-recipient><name><surname>Desai</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1655960</award-id><principal-award-recipient><name><surname>Desai</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM104239</award-id><principal-award-recipient><name><surname>Desai</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An anti-influenza receptor binding site antibody acquires breadth through hierarchical sets of epistatic mutations distributed across the light and heavy chains, demonstrating how mutations can interact to shape the evolution of antibody breadth in various antigen exposure regimens.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The diversity of influenza poses an ongoing public health challenge as vaccination and natural infection typically elicit immune responses that are highly strain-specific, and hence quickly lose efficacy as the virus evolves (<xref ref-type="bibr" rid="bib48">Kubo and Miyauchi, 2020</xref>; <xref ref-type="bibr" rid="bib7">Angeletti and Yewdell, 2018</xref>; <xref ref-type="bibr" rid="bib63">Neher and Bedford, 2015</xref>; <xref ref-type="bibr" rid="bib24">Dugan et al., 2020</xref>). This limited efficacy has garnered substantial interest in vaccination strategies that elicit broadly neutralizing antibodies (bnAbs) that neutralize diverse strains of influenza (<xref ref-type="bibr" rid="bib20">Corti et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Angeletti and Yewdell, 2018</xref>). Over the past two decades, there has been considerable effort to isolate and characterize anti-influenza bnAbs (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Throsby et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Corti et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>). These bnAbs target various conserved epitopes on the hemagglutinin (HA) influenza surface glycoprotein, including the receptor binding site (RBS) (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>), the stem or stalk domain (<xref ref-type="bibr" rid="bib18">Corti et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Ekiert et al., 2009</xref>), the lateral patch (<xref ref-type="bibr" rid="bib73">Raymond et al., 2018</xref>), and the membrane-proximal anchor site (<xref ref-type="bibr" rid="bib38">Guthmiller et al., 2022</xref>). BnAbs also vary in germline gene usage and breadth, with some binding several strains within an HA subtype and others binding nearly all characterized influenza strains (<xref ref-type="bibr" rid="bib20">Corti et al., 2017</xref>).</p><p>Despite the immense body of work on influenza bnAbs, we still do not fully understand the evolutionary processes through which they mature (<xref ref-type="bibr" rid="bib44">Jiang et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Horns et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Sangesland and Lingwood, 2021</xref>). Our strategies to elicit them therefore remain limited. It is clear, however, that distinct antibodies with diverse sequences can target the same HA epitope and evolve broad reactivity (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Ekiert et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>; <xref ref-type="bibr" rid="bib95">Wu et al., 2020a</xref>). This redundancy suggests that there are many possible evolutionary pathways to influenza bnAbs. Still, the relatively low frequencies at which they are observed in human repertoires following vaccination suggest that there are factors constraining their maturation that we do not yet fully appreciate (<xref ref-type="bibr" rid="bib94">Wu et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Bajic et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Horns et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Abbott et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Andrews et al., 2015</xref>).</p><p>High-throughput mutagenesis approaches are widely used as a tool to understand key properties shaping the evolution of numerous proteins (<xref ref-type="bibr" rid="bib82">Starr et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Miton and Tokuriki, 2016</xref>; <xref ref-type="bibr" rid="bib9">Bank et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Phillips et al., 2018</xref>). This work has revealed that new mutations can differentially impact distinct protein functions and often interact non-additively (i.e.<italic>, epistatically</italic>), potentially constraining the order in which they can occur (<xref ref-type="bibr" rid="bib91">Weinreich et al., 2006</xref>; <xref ref-type="bibr" rid="bib35">Gong et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Sailer and Harms, 2017</xref>). For antibodies, high-throughput mutagenesis studies have largely been limited to examining the effects of single mutations, either through saturating mutagenesis (e.g<italic>.,</italic> deep mutational scanning) of relatively small regions (<xref ref-type="bibr" rid="bib94">Wu et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Adams et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Forsyth et al., 2013</xref>) or through random mutagenesis (e.g.<italic>,</italic> error-prone PCR) (<xref ref-type="bibr" rid="bib52">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Amon et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Bowers et al., 2018</xref>). These methods examine the local mutational landscape of a particular antibody, or in other words, how single mutations can change affinity or breadth. The advantage of these methods is that the sequences analyzed are relatively unbiased, particularly for saturating mutagenesis, and thus one can surmise why particular mutations occurred naturally. For example, this approach identified many single amino acid substitutions in the anti-influenza bnAb C05 that improve affinity to different subsets of strains but typically reduce breadth (<xref ref-type="bibr" rid="bib94">Wu et al., 2017</xref>).</p><p>A key limitation of saturating mutagenesis approaches is that they cannot probe how epistatic interactions between mutations might constrain antibody evolutionary trajectories, which typically involve multiple mutations (<xref ref-type="bibr" rid="bib88">Victora and Nussenzweig, 2012</xref>). Because antibodies acquire numerous mutations and experience fluctuating selection pressures on short timescales (<xref ref-type="bibr" rid="bib88">Victora and Nussenzweig, 2012</xref>; <xref ref-type="bibr" rid="bib80">Smith et al., 2004</xref>), they are necessarily distinct from other proteins for which epistasis has been studied. Moreover, they bind antigens through disordered loops, in contrast to the structured active sites of most enzymes, and they are relatively tolerant to mutations (<xref ref-type="bibr" rid="bib13">Braden et al., 1998</xref>; <xref ref-type="bibr" rid="bib14">Burks et al., 1997</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 1999</xref>; <xref ref-type="bibr" rid="bib46">Klein et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Corti and Lanzavecchia, 2013</xref>). Further, the evolutionary dynamics of affinity maturation are defined by discrete rounds of mutation and selection compared to the more continuous processes most proteins are subject to, and thus mutations that occur concurrently are selected based on their collective rather than individual effects (<xref ref-type="bibr" rid="bib88">Victora and Nussenzweig, 2012</xref>; <xref ref-type="bibr" rid="bib85">Unniraman and Schatz, 2007</xref>). For these reasons, the evolutionary constraints on antibodies may be unique.</p><p>The few studies that have examined epistasis in antibodies indicate that it is a key determinant of affinity (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Pappas et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Adams et al., 2019</xref>). For example, multiple studies have identified mutations that interact synergistically to bind an antigen (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Pappas et al., 2014</xref>). Still, most of this work has focused on interactions between a small subset of mutations (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). Addressing the prevalence and general importance of epistasis in shaping antibody evolution will require more comprehensive combinatorial mutagenesis strategies that sample combinations of mutations present in each somatic antibody sequence (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). These combinatorial strategies, however, do not capture epistasis with other mutations that could have occurred in alternative evolutionary pathways, which will require integrating combinatorial mutagenesis with the saturating mutagenesis methods described above.</p><p>In previous work, we systematically mapped the relationship between antibody sequence and affinity (the sequence-affinity landscape) across mutational landscapes relevant for the somatic evolution of two stem-targeting bnAbs of varying breadth, CR6261 and CR9114 (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). We found that affinity was determined by nonadditive interactions between mutations, and that such epistasis could both constrain and potentiate the acquisition of breadth. Notably, the nature of this epistasis varied considerably between the two bnAbs. For CR6261, epistatic interactions were similar for binding distinct group 1 strains, thus evolutionary pathways could simultaneously improve in affinity to divergent antigens. For CR9114, increasingly divergent antigens required additional epistatically interacting mutations such that evolutionary pathways were constrained to improve in affinity to one antigen at a time. The distinct topologies of these sequence-affinity landscapes result from differences between the various antigens and the mutations that are required for binding.</p><p>Although anti-stem bnAbs are among the broadest influenza bnAbs characterized, they are a small and biased subset of the influenza antibody response. Despite the presence of anti-stem antibodies in human sera (<xref ref-type="bibr" rid="bib99">Yassine et al., 2018</xref>) and the ability to drive viral escape mutants in vitro (<xref ref-type="bibr" rid="bib96">Wu et al., 2020b</xref>), the stem is minimally mutated amongst circulating viral strains and does not appear to be evolving in response to these antibodies, possibly due to the high concentration of antibody required for protection (<xref ref-type="bibr" rid="bib27">Ellebedy, 2018</xref>; <xref ref-type="bibr" rid="bib40">Han et al., 2021</xref>) and immune pressure. In contrast, due to the small size of the RBS pocket, RBS-directed bnAbs frequently make contacts with immunodominant epitopes surrounding the pocket that have substantial antigenic variation (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Schmidt et al., 2015b</xref>; <xref ref-type="bibr" rid="bib50">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Krause et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Guthmiller et al., 2021</xref>). Although RBS-directed bnAbs have a relatively narrower reactivity profile compared to anti-stem bnAbs, they are potently neutralizing, do not require effector functions for potent in vivo protection as do anti-stem bnAbs (<xref ref-type="bibr" rid="bib18">Corti et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">DiLillo et al., 2014</xref>), and have evolved broad recognition despite the accumulation of antibody escape mutations in the periphery of the RBS. Further, RBS-directed bnAbs can mature from diverse germline V<sub>H</sub> and V<sub>L</sub> genes (<xref ref-type="bibr" rid="bib79">Schmidt et al., 2015b</xref>), suggesting that there are likely numerous evolutionary pathways to target this epitope. Thus, to understand more generally how epistasis constrains bnAb evolution, here we consider RBS-directed bnAbs as they target an entirely different epitope under distinct immune selection pressures.</p><p>Specifically, we examine the influence of epistasis on the evolution of a well-characterized RBS-directed bnAb, CH65, which binds and neutralizes diverse H1 strains (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>). CH65 was isolated from a donor 7 days post-vaccination. The unmutated common ancestor (UCA) and an early intermediate (I-2) have moderate affinity for a subset of H1 strains that circulated early in the donor’s lifetime (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). The affinity-matured CH65 has 18 mutations throughout the light (V<sub>L</sub>) and heavy (V<sub>H</sub>) variable regions, which improve affinity to strains that circulated early in the donor’s life and confer affinity to antigenically drifted strains (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). Thus, CH65 evolved to acquire affinity to emerging strains without compromising affinity for previously circulating strains.</p><p>The structural changes upon affinity maturation of CH65 and clonally related antibodies have been extensively characterized (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). This work showed that CH65 primarily matures by preconfiguring the HCDR3 loop into its binding conformation, thereby minimizing the conformational entropic cost of binding (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>). Importantly, none of the 18 somatic mutations are in the HCDR3; rather, key mutations in HCDR1, HCDR2, and LCDR1 result in contacts that stabilize the HCDR3 loop in its binding-compatible conformation (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). This structural characterization, in addition to molecular dynamics simulations, identified specific mutations that are critical for breadth, including some that interact synergistically to stabilize the HCDR3 loop (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). In theory, such epistasis could constrain bnAb evolution by requiring multiple mutations to confer a selective advantage, or alternatively, it could compensate for the deleterious effects of other mutations and favor selection of bnAbs.</p><p>Given that many mutations in CH65 are important for imparting affinity to HA, including those at distant sites (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>), we hypothesized that there are many sets of epistatic mutations in CH65 not previously identified, particularly because long-range epistatic interactions are difficult to predict from structural analyses alone. In contrast to the anti-stem bnAbs described above (<xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>; <xref ref-type="bibr" rid="bib54">Lingwood et al., 2012</xref>), CH65 engages HA through both light and heavy chain contacts and requires mutations in both chains to bind divergent antigens (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). Thus, it is likely that mutations interact epistatically both within and between the heavy and light chains. Despite the potential importance of these interactions in shaping the evolution of CH65, and the numerous other antibodies that engage antigens using both chains (<xref ref-type="bibr" rid="bib18">Corti et al., 2011</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>; <xref ref-type="bibr" rid="bib97">Xiao et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Ekiert and Wilson, 2012</xref>), characterizations of inter-chain epistasis have so far been limited to small sets of a few mutations (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). Although these smaller datasets have revealed some important inter-chain epistatic interactions, they measure a subset of interactions selected based on structural data, and thus we still do not know the magnitude or prevalence of this epistasis and hence how important it is in shaping antibody evolution.</p><p>Here, to elucidate the role of epistasis (both inter- and intra-chain) in shaping the evolution of an RBS antibody, we systematically characterize the CH65 sequence-affinity landscape. Specifically, we generate a combinatorially complete antibody library containing all possible evolutionary intermediates between the UCA and the mature somatic sequence (N=2<sup>16</sup> = 65,536) and measure affinity to three antigenically distinct H1 strains to assess how epistasis can shape evolutionary pathways, leading to varying levels of breadth. We find that strong high-order epistasis constrains maturation pathways to bind antigenically distinct antigens. Although fewer epistatic mutations are needed to bind an antigen similar to that bound by the UCA, these sets of mutations overlap with those required to bind a more divergent antigen. Collectively, these landscapes provide mechanistic insight into how affinity maturation responds to an evolving epitope and how exposure history can influence future immune responses. In combination with our previous work on anti-stem bnAbs (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>), this work shows how epistasis can differentially impact the evolutionary trajectories of bnAbs of varying breadth, epitope, and variable chain gene usage.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>To comprehensively examine how epistasis may have shaped the evolution of CH65, we generated a combinatorially complete antibody library comprising all possible evolutionary intermediates from the UCA to CH65. This library contains all possible combinations of mutations present in both the variable heavy and light chains of CH65, less two mutations (Q1E and S75A in V<sub>H</sub>) distant from the paratope that do not significantly impact binding affinity (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) or physically interact with other residues. Removing these mutations results in a final library size of 2<sup>16</sup>, which is within the throughput limit of our methods.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>CH65 sequence-affinity landscape.</title><p>(<bold>A</bold>) Alignment of unmutated common ancestor (UCA), I-2, and CH65 V<sub>H</sub> (top) and V<sub>L</sub> (bottom) sequences. Mutations of interest are shown in purple and are numbered; gray mutations do not impact affinity and were excluded from the library. (<bold>B</bold>) -log<italic>K</italic><sub>D</sub> for ~2<sup>16</sup> variants to each of the three antigens. Each point represents the mean -log<italic>K</italic><sub>D</sub> of biological duplicates and is colored by the number of somatic mutations in the corresponding variant. The UCA, I-2, and CH65 are annotated as stars; N = 62,926 after filtering poor <italic>K</italic><sub>D</sub> measurements from the Tite-Seq data (see 'Materials and methods'). Two-dimensional representations of the data are shown below the three-dimensional plot. (<bold>C</bold>) Distribution of -log<italic>K</italic><sub>D</sub> for each antigen. Left: variant -log<italic>K</italic><sub>D</sub> grouped by the number of somatic mutations; Right: -log<italic>K</italic><sub>D</sub> histograms for variants that bind each antigen, with total number of binding variants (N) indicated on plot.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>CH65 library expression and -log<italic>K</italic><sub>D</sub> to MA90, MA90-G189E, and SI06.</title><p>Biological duplicates, mean, and standard error are reported.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83628-fig1-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Isogenic flow cytometry measurements of -log<italic>K</italic><sub>D</sub> and expression for select CH65 variants.</title><p>Mean and standard error for -log<italic>K</italic><sub>D</sub> and expression are reported for biological duplicates, alongside the corresponding Tite-Seq -log<italic>K</italic><sub>D</sub> and expression measurements (as in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83628-fig1-data2-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>CH65 mutation reversion.</title><p>Isogenic measurements of -log<italic>K</italic><sub>D</sub> for CH65 with (18-mut) and without (16-mut) Q1E and S75A to MA90 (p-value=0.82, <italic>t</italic>-stat = 0.26) and SI06 (p-value=1.0, <italic>t</italic>-stat = 0.0); ‘ns’ designates a p-value&gt;0.05. Error bars indicate standard error between biological duplicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Tite-Seq workflow.</title><p>Combinatorially complete (N = 2<sup>16</sup> variants) antibody plasmid library is transformed into yeast and expression of antibodies is induced. Yeast antibody library is then labeled with HA (at varying concentrations) followed by fluorophores (FITC, which binds the Ab, and PE, which binds HA). Labeled yeast library is then gated to select single cells that express scFv. scFv-positive cells are then sorted according to HA binding (PE fluorescence) into four bins. Bin 1 corresponds to all HA-negative cells, HA-positive cells are split evenly between the remaining three bins. Each bin is then sequenced to determine variant frequency in each bin. <italic>K</italic><sub>D</sub> is then inferred by fitting the mean bin each variant is observed in to the antigen concentration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig1-figsupp2-v3.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Tite-Seq <italic>K</italic><sub>D</sub> quality control and isogenic measurements.</title><p>(<bold>A</bold>) Correlation between biological duplicate Tite-Seq K<sub>D</sub> measurements before (top) and after (bottom) removing genotypes with -log<italic>K</italic><sub>D</sub> differing by more than one-log between biological replicates. The latter set of measurements were used for all downstream analyses. <italic>N</italic> indicates the number of variants plotted, <italic>r</italic> indicates the correlation between biological replicates. (<bold>B</bold>) Correlation between Tite-Seq -log<italic>K</italic><sub>D</sub> measurements and isogenic fluorescence-based -log<italic>K</italic><sub>D</sub> measurements for a subset of mutants to one of the three antigens, as indicated in key. Points and error bars indicate the mean and SEM between biological replicates, respectively; SEM are generally smaller than the points. (<bold>C</bold>) Correlation between Tite-Seq -log<italic>K</italic><sub>D</sub> measurements and BLI -log<italic>K</italic><sub>D</sub> measurements for a subset of mutants to one of the three antigens, as indicated in key. Error bars indicate the SEM between biological replicates (for Tite-Seq) and the SE of the fit (for BLI) and are generally smaller than the points.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig1-figsupp3-v3.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>CH65 library expression.</title><p>(<bold>A</bold>) Sorting scheme for scFv expression. Library was sorted into four bins, each comprising 25% of the total population, along the log(fluorescence) axis corresponding to expression (FITC). (<bold>B</bold>) Correlation between Tite-Seq biological replicate measurements of expression for all variants in the CH65 library. (<bold>C</bold>) Correlation between mean Tite-Seq expression measurement and mean isogenic expression measurement for select variants. (<bold>D</bold>) Change in expression resulting from mutation as a function of the number of other mutations present. (<bold>E</bold>) Change in expression resulting from each mutation. Each violin contains 2<sup>15</sup> points corresponding to the effect of that mutation on the 2<sup>15</sup> other genetic backgrounds. White, gray, and black points show the impact of the mutation on expression on the unmutated common ancestor (UCA), I-2, and CH65 genetic backgrounds, respectively. (<bold>F</bold>) Relationship between expression and binding affinity for all variants in the CH65 library. (<bold>G</bold>) Relationship between mean change in expression and mean change in binding affinity resulting from each of the 16 mutations in CH65. Mutations are colored as in (<bold>E</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig1-figsupp4-v3.tif"/></fig></fig-group><p>To profile the breadth of the corresponding antibody library, we first transform this combinatorial plasmid library into yeast for antibody surface display in a single-chain variable fragment (scFv) format (<xref ref-type="bibr" rid="bib11">Boder and Wittrup, 1997</xref>). We then use Tite-Seq (<xref ref-type="bibr" rid="bib3">Adams et al., 2016</xref>), a high-throughput method that couples flow cytometry with sequencing, to measure equilibrium binding affinities to three H1 strains bound by CH65. We chose these strains to sample varying levels of antigenic change (<xref ref-type="bibr" rid="bib80">Smith et al., 2004</xref>; <xref ref-type="bibr" rid="bib10">Bedford et al., 2014</xref>): they include a strain that circulated early in the donor’s lifetime (A/Massachusetts/1/1990, 'MA90') and a strain that circulated 16 years later (A/Solomon Islands/3/2006, 'SI06') (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>). Additionally, because affinity maturation has been shown to confer binding to antigens that escape less mutated members of the same lineage (<xref ref-type="bibr" rid="bib62">Muecksch et al., 2021</xref>), we drove viral escape of MA90 in vitro using the UCA and found that CH65 could bind to the resulting strain (A/Massachusetts/1/1990 G189E, 'MA90-G189E') that escapes the UCA. We use the MA90-G189E antigen to profile incremental antigenic change from MA90 (one direct escape mutation), whereas SI06 represents more substantial antigenic change during natural evolution, including loss of K133a and the mutation E156G in the RBS.</p><p>For each of these three antigens, we used Tite-Seq to measure equilibrium binding affinities for all 2<sup>16</sup> variants in biological duplicates (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). We log-transform the binding affinities and report -log<italic>K</italic><sub>D</sub>, which is proportional to the free energy change of binding (and is thus expected to combine additively) (<xref ref-type="bibr" rid="bib92">Wells, 1990</xref>; <xref ref-type="bibr" rid="bib65">Olson et al., 2014</xref>). For each antigen, the Tite-Seq -log<italic>K</italic><sub>D</sub> correlate well between biological replicates (<italic>r</italic> ~ 0.98 for all antigens; <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>) and accurately reflect isogenic measurements made by flow cytometry (<italic>r</italic> = 0.97; <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>), as well as recombinant IgG affinity measurements made by biolayer interferometry (<italic>r</italic> = 0.86; <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>).</p><sec id="s2-1"><title>CH65 sequence-affinity landscape</title><p>Broadly, we find that increasingly divergent antigens require additional mutations to confer antigen binding. Consistent with previous work (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>), the UCA has weak affinity for MA90 but does not bind MA90-G189E or SI06; I-2 (which contains G31D, M34I, and N52H (V<sub>H</sub>)) has improved affinity to MA90, weak affinity to MA90-G189E, and does not bind SI06; and CH65 has near maximal affinity amongst library variants for all three antigens (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). While the entire library binds MA90, ~83% of variants bind MA90-G189E and ~51% of variants bind SI06 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). For all antigens, affinity is higher for more mutated variants, except for a subset of highly mutated variants that do not bind SI06 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, bottom right). There are ~2000 variants that bind MA90 with reduced affinity relative to the UCA; none of these variants have detectable affinity for SI06, and only one has detectable affinity for MA90-G189E (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Further, all variants that bind SI06 also bind MA90-G189E (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) as variants can bind MA90-G189E with fewer mutations than SI06 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This 'hierarchical' or 'nested' pattern, where mutations that enable binding to more antigenically divergent strains are dependent on mutations that enable binding to less divergent strains, is reminiscent of what we observed previously for the anti-stem bnAb CR9114 (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>), despite the comparatively subtle differences between the antigens examined here (83–96% epitope identity versus 52–61% for the CR9114 antigens) (<xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>).</p></sec><sec id="s2-2"><title>Mutational effects on CH65 affinity and breadth</title><p>To understand how specific mutations shape the sequence-affinity landscape, we computed the change in affinity resulting from each of the 16 mutations on all 2<sup>15</sup> genetic backgrounds at the other 15 sites. This analysis reveals that several mutations improve affinity to MA90 and MA90-G189E (e.g<italic>.,</italic> Y35N, Y48C, D49Y (V<sub>L</sub>) and G31D, Y33H, H35N, N52H (V<sub>H</sub>)), and some of these distributions are multimodal, indicating that their effect on affinity depends on the presence of other mutations (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consistent with this, some mutations improve affinity to MA90 and/or MA90-G189E on the UCA or I-2 backgrounds (e.g<italic>.,</italic> Y35N (V<sub>L</sub>) and Y33H, H35N (V<sub>H</sub>)) and others on the CH65 background (Y48C, D49Y (V<sub>L</sub>)). For SI06, N52H dramatically improves affinity and most variants lacking this mutation do not have detectable affinity. Thus, several mutations (e.g<italic>.,</italic> Y35N (V<sub>L</sub>)) improve affinity to SI06 in the I-2, but not the UCA, background (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In general, the effects of these mutations correlate between the different antigens, with mutations affecting affinity more substantially for MA90-G189E and SI06 compared to MA90 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mutational effects on affinity.</title><p>(<bold>A</bold>) Change in -log<italic>K</italic><sub>D</sub> resulting from each mutation on all ~2<sup>15</sup> genetic backgrounds. Impact of mutation on the unmutated common ancestor (UCA), I-2, and the CH65 genetic backgrounds are represented by white, gray, and black points, respectively. (<bold>B</bold>) Correlation of mean effect on -log<italic>K</italic><sub>D</sub> for MA90, SI06, and MA90-G189E resulting from each mutation. Regression line and 95% confidence intervals are shown in gray. Mutations are colored as in (<bold>A</bold>). (<bold>C</bold>) Frequency of each mutation amongst variants that bind a given antigen with <italic>K</italic><sub>D</sub> ≤ 1 nM. Error bars correspond to standard deviation across bootstrapped data (N = 10). (<bold>D</bold>) Mutations present at &gt;55% frequency (p-value&lt;0.05 from one-sided <italic>t</italic>-test) amongst binders for each antigen. <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref><italic>.</italic> Change in -log<italic>K</italic><sub>D</sub> resulting from each mutation as a function of the number of other mutations present.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Change in -log<italic>K</italic><sub>D</sub> resulting from each mutation as a function of the number of other mutations present.</title><p>Line represents mean, and shading represents 95% confidence interval over all genetic backgrounds (N ~ 2<sup>15</sup>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig2-figsupp1-v3.tif"/></fig></fig-group><p>To assess which mutations confer affinity to a particular antigen, we computed the frequency of each mutation amongst binding variants in the library. Consistent with the landscapes in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, we observe that the mutations enriched amongst binders form a hierarchical pattern between the antigens (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). For example, a few mutations are enriched (≥55% frequency) amongst variants with nanomolar affinity for MA90 (e.g<italic>.,</italic> Y35N, D49Y (V<sub>L</sub>) and Y33H, N52H (V<sub>H</sub>)), a few additional mutations are enriched amongst MA90-G189E binders (e.g<italic>.,</italic> S29R (V<sub>L</sub>) and G31D, H35N, R87K (V<sub>H</sub>)), and still additional mutations are enriched amongst SI06 binders (e.g., N26D, Y48C, V98I (V<sub>L</sub>) and M34I, R85G (V<sub>H</sub>)) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Thus, except for Y35N (V<sub>L</sub>), which is interestingly depleted amongst SI06 binders (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), the mutations that enhance affinity to the three antigens form a hierarchical pattern.</p><p>We next characterized how epistasis between these mutations might impact affinity and result in this hierarchical pattern of breadth. To this end, we fit our measured -log<italic>K</italic><sub>D</sub> to a standard biochemical model of epistasis (<xref ref-type="bibr" rid="bib75">Sailer and Harms, 2017</xref>), which is a linear model defined as the sum of single mutational effects and epistatic terms up to a specified order (see 'Materials and methods'). Using a cross-validation approach, we find that the optimal order model for affinity is fourth-order for MA90 and fifth-order for MA90-G189E and SI06, and we report coefficients at each order from these best-fitting models (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The magnitude and sign of these coefficients correspond to effects on -log<italic>K</italic><sub>D</sub>: for example, a second-order term of +1 means that two mutations occurring together improve -log<italic>K</italic><sub>D</sub> by 1 unit, beyond the sum of their first-order effects. For all three antigens, we find widespread epistasis between mutations in the same chain and between mutations in different chains, with many epistatic terms exceeding first-order effects in magnitude (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In contrast to our previous work on variable heavy-chain-only antibody landscapes (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>), we find many strong epistatic interactions between mutations that are too distant to physically interact (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s4">4</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Epistatic coefficients for biochemical model of epistasis.</title><p>(<bold>A</bold>) Significant first-order, pairwise, and higher-order mutational effects for each of the 16 mutations inferred from the optimal order model for each antigen. Higher-order effects are reported as a sum. Mutations present in I-2 are shown in bold. ‘R’ indicates that the mutation is required for binding (defined as being present in ≥90% of binding variants) and is thus excluded from the epistasis inference. (<bold>B</bold>) Structural context of significant first-order and epistatic effects. For each mutation, the upper triangle shows the first-order effect, the lower triangle shows the sum of the pairwise and higher-order effects, and the contact surface area with HA and HCDR3 are shown in the fourth and fifth columns. Significance in (<bold>A</bold>) and (<bold>B</bold>) indicates the coefficient 95% CIs do not include zero, see 'Materials and methods' and <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref><italic>.</italic> Pairwise effects versus distance.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Interaction model coefficients for CH65.</title><p>Coefficients are reported for each antigen, with standard errors, p-values, and 95% confidence intervals.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83628-fig3-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Pairwise effects versus distance.</title><p>(<bold>A</bold>) Pairwise coefficients plotted as a function of the distance between alpha-carbons (in Angstroms) of the corresponding residues. Select outliers are annotated. (<bold>B</bold>) Left: mean pairwise coefficients between residues, binned according to the distance between alpha-carbons (in 4-Angstrom bins). Right: same data as left, but coefficients were permuted to generate null expectation. Error bars correspond to standard deviation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Biochemical epistasis within heavy and light chains and between chains.</title><p>(<bold>A</bold>) Sum of absolute value of statistically significant pairwise and higher-order coefficients for MA90, MA90-G189E, and SI06. Significant coefficients are defined as those with 95% CI that do not include zero. (<bold>B</bold>) Significant epistatic coefficients between mutations in the light chain (VL), heavy chain (VH), or between mutations spread across both chains (both). Percentage of insignificant coefficients is indicated below each swarm plot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp2-v3.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Epistatic coefficients for statistical model of epistasis.</title><p>Significant first-order, pairwise, and higher-order mutational effects for each of the 16 mutations inferred from the optimal order model for each antigen. Higher-order effects are reported as a sum. Mutations present in I-2 are shown in bold. ‘R’ indicates that the mutation is required for binding (defined as being present in ≥90% of binding variants) and is thus excluded from the epistasis inference. Significant coefficients are defined as those with 95% CI that do not include zero.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp3-v3.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Comparison of coefficients in biochemical and statistical models.</title><p>Total number of statistically significant coefficients is plotted for each antigen and epistatic model. Significant coefficients are defined as those with 95% CI that do not include zero.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp4-v3.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>First-order and epistatic effects plotted on co-crystal structure for each antigen.</title><p>Absolute value of first-order mutational effects (<bold>A</bold>) and sum of absolute value of pairwise and higher-order (i.e<italic>.,</italic> epistatic) mutational effects (<bold>B</bold>) on affinity to each antigen mapped onto the antibody-antigen co-crystal structure (5UGY). Mutations in CH65 relative to unmutated common ancestor (UCA) are shown as sticks; first-order and epistatic effects are colored on the same numeric color scale for each antigen.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp5-v3.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Variance partitioning of statistical epistasis coefficients by order of interaction.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig3-figsupp6-v3.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Structural and biophysical basis of epistasis in CH65</title><p>Because there are substantial long-range epistatic interactions, our combinatorial approach identifies numerous interactions not previously known, in addition to confirming the few interactions characterized in earlier work (e.g<italic>.,</italic> Y48C and D49Y (V<sub>L</sub>) have strong synergistic epistasis) (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>). Here, we find strong epistasis between the I-2 mutations (G31D, M34I, N52H (V<sub>H</sub>)), neighboring mutations (Y33H, H35N (V<sub>H</sub>)), mutations known to stabilize light chain contacts (Y48C, D49Y) (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>), as well as an uncharacterized light chain mutation (Y35N). When we examine the structural context of this epistasis, we find that mutations with strong first-order and epistatic effects often make contact with either HA or with the HCDR3 that engages the RBS (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>). This suggests that the effects of these mutations are either mediated through the contacts that they make with HA or through affecting the HCDR3 loop conformation. These mutations interact epistatically for each of the three antigens, though the magnitude of epistasis is higher for SI06 (explaining ~34% of the variance in <italic>K</italic><sub>D</sub>, relative to ~24% for MA90, and ~25% for MA90-G189E, see <xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>).</p><p>Importantly, these epistatic interactions are essential for the acquisition of affinity to both MA90-G189E and SI06. To investigate the molecular details of this epistasis, we compared the previously determined crystal structures of the unbound UCA, I-2, CH65, and CH65 bound to SI06 (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Lee et al., 2015</xref>), as well as newly determined crystal structures of the unbound UCA with Y35N (V<sub>L</sub>) and I-2 with Y35N (V<sub>L</sub>) and H35N (V<sub>H</sub>). Additionally, we produced several variants as recombinant IgG to assay the binding kinetics by biolayer interferometry. To mimic the Tite-Seq system, IgG was bound to biosensors and assayed for binding to full-length trimeric HA (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplements 2</xref>–<xref ref-type="fig" rid="fig4s4">4</xref>). Here, we focus on binding kinetics of minimally mutated variants that confer affinity to each antigen but binding of 12 variants was assayed to all three antigens at varying temperatures (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>).</p><p>The I-2 intermediate (which contains G31D, M34I, N52H (V<sub>H</sub>)) is amongst the least-mutated variants that binds MA90-G189E (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The N52H mutation, which substantially improves affinity to MA90-G189E (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), would potentially clash with one of the binding-incompatible HCDR3 conformations observed in crystal structures of the UCA and I-2; thus, this mutation may increase the occupancy of the binding-compatible HCDR3 conformation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). In the bound state, N52H π-stacks with Y33H and hydrogen bonds with G31D (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Consequently, N52H and G31D, which together provide high affinity for MA90-G189E (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), form a network of interactions between HCDR1, HCDR2, and the 150-loop of HA to stabilize the binding interaction (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Thus, while N52H alone confers affinity to MA90-G189E, G31D and M34I (I-2) reduce the dissociation rate by ~3.5–5-fold to improve affinity (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>). Notably, these interactions are distant (~15–20 Å) from the residue conferring viral escape, precluding any direct interaction (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Though these mutations are also important for affinity to the antigenically drifted SI06, they are insufficient to confer appreciable affinity in the absence of other epistatic mutations (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, top).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Structural basis of epistasis in CH65.</title><p>(<bold>A</bold>) Three mutations in I-2 (G31D, M34I, N52H) confer affinity to MA90-G189E. Each violin contains 64 genotypes that have the unmutated common ancestor (UCA) residue at positions 35, 48, 49 (V<sub>L</sub>) and 33, 35, 85, 87 (V<sub>H</sub>), and are variable at the remaining six positions. In (<bold>A</bold>) and (<bold>D</bold>), the white dots indicate the distribution means, and the gray and dotted lines indicate the additive and pairwise expectations, respectively. (<bold>B</bold>) Epistatic mutations that confer affinity to viral escape strains are distant from the sites of escape. Shown is CH65 bound to SI06 (PDB 5UGY; <xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>). Colored residues highlight the locations of the mutations shown in (<bold>A</bold>) and (<bold>D</bold>). Spheres highlight the locations of the viral escape mutations (G189E, ∆K133a, and E156G). (<bold>C</bold>) Top, left: mutations N52H and G31D establish a network of interactions between HCDR1, HCDR2, and HA. Top, right: distance between G189E and N52H or G31D precludes interaction. Alpha carbon distances are shown. Bottom: Binding kinetics against MA90-G189E for select variants at 30°C by biolayer interferometry using a bivalent analyte binding model. (<bold>D</bold>) Mutations in I-2 are insufficient for affinity to SI06 (top) but interact epistatically with Y35N and H35N to bind SI06 (bottom). Top: each violin contains 64 genotypes that have the UCA residue at positions 35, 48, 49 (V<sub>L</sub>) and 33, 35, 85, 87 (V<sub>H</sub>), and are variable at the remaining six positions. Bottom: each violin contains 64 genotypes that have the UCA residue at positions 48, 49 (V<sub>L</sub>) and 33, 85, 87 (V<sub>H</sub>), the CH65 residue at positions 31 and 34 (V<sub>H</sub>), and are variable at the remaining six positions. ‘<inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>∅</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>’ and ‘+’ indicate mutations that have neutral or beneficial mean effects on -log<italic>K</italic><sub>D</sub>, respectively. (<bold>E</bold>) Left: epistatic mutations Y35N and H35N are located at the VH-VL interface. Right: somatic mutations remove interactions with the HCDR3. Shown is the unbound I-2 structure (PDB 4HK3 <xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>). Bottom: binding kinetics against SI06 for select variants at 30°C by biolayer interferometry using a bivalent analyte binding model.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Binding kinetics for selected antibody variants determined by biolayer interferometry.</title><p>Association rates, dissociation rates, and dissociation constants are reported for 12 antibody variants at multiple temperatures against MA90, MA90-G189E, and SI06. Standard errors for each parameter, χ<sup>2</sup>, and R<sup>2</sup> values are reported from global curve fitting using the bivalent analyte model.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83628-fig4-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>X-ray data collection and refinement statistics for unbound Fabs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83628-fig4-data2-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Structural analysis of HCDR3 conformations observed in crystal structures of unbound and bound Fabs in the CH65 lineage.</title><p>(<bold>A</bold>) The mutation N52H in CH65 (PDB 4WUK (unbound) and 5UGY (bound)) clashes with E102 in the HCDR3 conformations observed in the unbound crystal structures of the unmutated common ancestor (UCA) (PDB 4HK0) and I-2 (PDB 4HK3). (<bold>B</bold>) Residue 52H moves to π-stack with residue 33 in a T configuration in CH65 compared to hydrogen bonding between 52H and 33Y in unbound I-2. (<bold>C</bold>) Unbound Fab structures of several variants in the CH65 lineage. Cartoon volume is scaled by B factors. Previously reported structures show that the HCDR3 conformation in the UCA and I-2 is different than that in CH65, which matches the bound conformation (top). Although the UCA with the Y35N mutation confers affinity to MA90-G189E, the HCDR3 is not in the binding conformation and has exceedingly high B factors (bottom left). Similarly, although the I-2 with the mutations Y35N and H35N confer affinity to SI06, the HCDR3 lacked sufficient density and also had high B factors (bottom middle).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Representative biolayer interferometry binding traces against MA90 for the indicated antibodies (left) and temperatures (top).</title><p>Black is the processed data and red is the global curve fit using the bivalent analyte model.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Representative biolayer interferometry binding traces against MA90-G189E for the indicated antibodies (left) and temperatures (top).</title><p>Black is the processed data and red is the global curve fit using the bivalent analyte model. For the unmutated common ancestor (UCA), there was no detectable binding.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp3-v3.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Representative biolayer interferometry binding traces against SI06 for the indicated antibodies (left) and temperatures (top).</title><p>Black is the processed data and red is the global curve fit using the bivalent analyte model. For the unmutated common ancestor (UCA) and I-2, any signal was too weak for analysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp4-v3.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Summary of all association rates, dissociation rates, and dissociation constants measured by BLI against MA90, MA90-G189E, and SI06 at multiple temperatures.</title><p>Error bars represent the standard error for kinetic parameters derived from global curve fitting with a bivalent analyte model using the analysis software supplied with the instrument (Sartorius Data Analysis HT 12.0.2.59). For some high-affinity variants, the dissociation time was too short to accurately measure the dissociation rate against MA90 accurately, especially at lower temperatures (left), resulting in inaccurate dissociation rates with large errors. Antibodies that did not bind MA90-G189E (middle) or SI06 (right) were not included in the plots.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp5-v3.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Biolayer interferometry binding traces for the antibody variant containing the I-2 mutations (G31D, M34I, and N52H) in addition to H35N and Y35N for the indicated antigens (left) and temperatures (top).</title><p>Weak but detectable binding is observed for SI06.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig4-figsupp6-v3.tif"/></fig></fig-group><p>In examining the minimally mutated variants that can bind SI06, we find that Y35N in the light chain and H35N in the heavy chain interact synergistically with the I-2 mutations (G31D, M34I, N52H) to confer affinity to SI06 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, bottom). Thus, the hierarchical sets of mutations that confer broad reactivity to these antigens (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) do so through epistasis. In particular, the germline residue Y35 in the light chain framework (FWR) 2 is part of a cluster of aromatic residues at the V<sub>H</sub>-V<sub>L</sub> interface and makes π-stacking, methionine–aromatic, and hydrogen bonding interactions between LFWR2 and LCDR3, HCDR3, and HFWR4 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The somatic mutation Y35N effectively removes these interactions with the HCDR3. Although the loss of the aromatic moiety from tyrosine to asparagine likely has a destabilizing effect, we attribute the observed changes in affinity to the loss of hydrogen bonding between LFWR2 and HCDR3; this is in part because the lineage member CH67, which has similarly broad reactivity, acquires a Y35F mutation upon affinity maturation that is only a removal of a hydroxyl group, preventing the ability to form hydrogen bonding interactions through the side chain (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>). Similarly, H35N removes a methionine–aromatic interaction, known to have a stabilizing effect in proteins (<xref ref-type="bibr" rid="bib86">Valley et al., 2012</xref>), between the HFWR2 and HCDR3 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Addition of Y35N and H35N into the UCA background did not confer affinity to SI06 (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). However, the addition of H35N into the I-2 background produced weak but detectable affinity with an association rate that was improved upon addition of Y35N (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>, <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>). Notably, while Y35N confers affinity to SI06 for variants with few somatic mutations, the magnitude of this effect diminishes as the number of mutations increases. Indeed, Y35N is depleted amongst the highest affinity variants (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and in the context of a mutated background decreased the association rate and overall affinity (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), suggesting that Y35N, which removes inter-chain contacts, is likely only beneficial during early rounds of affinity maturation.</p><p>Previous studies on this lineage (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Xu et al., 2015</xref>) showed that HCDR3 rigidification contributed to high-affinity binding to SI06: crystal structures of the unbound, affinity-matured Fabs had the same HCDR3 configurations as those in the antigen-bound state; the UCA and I-2, however, were either disordered or constrained, due to crystal packing, in a binding-incompatible state. To determine whether the mutations Y35N and H35N could stabilize a binding-compatible HCDR3 conformation, we determined X-ray crystal structures of unbound Fabs containing Y35N in the UCA background or Y35N and H35N in the I-2 background and compared them to previously determined structures (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). These variants were insufficient to rigidify the HCDR3 as observed by the HCDR3 conformation and high B factors or the lack of density corresponding to the HCDR3 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). These data show that the I-2 mutations conferred affinity towards MA90-G189E by stabilizing the HCDR1 and HCDR2 with HA and were required for the addition of Y35N and H35N, which remove contacts with HCDR3, to confer affinity against SI06 without complete HCDR3 rigidification, revealing a biophysical mechanism through which inter-chain epistasis can determine broad affinity in a hierarchical manner.</p></sec><sec id="s2-4"><title>Likelihood of mutational pathways to CH65</title><p>The extent of epistasis we observe suggests that the evolution of CH65 is contingent on mutations occurring in a particular order. Further, the hierarchical pattern of mutations that confer affinity to the different antigens indicates that the likelihood a mutation fixes depends on the selecting antigen. Because we measured affinities for a combinatorially complete library, we can infer the likelihood of all possible evolutionary trajectories from the UCA to CH65 (with and without the constraint of passing through the I-2 intermediate) in the context of various possible antigen selection scenarios (e.g.<italic>,</italic> maturation to MA90 alone, or to SI06 alone, etc.). To this end, we implement a framework in which the probability of any mutational step is higher if -log<italic>K</italic><sub>D</sub> increases and lower if -log<italic>K</italic><sub>D</sub> decreases (see 'Materials and methods'; <xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). We use -log<italic>K</italic><sub>D</sub> to each antigen to compute the likelihood of all possible mutational trajectories in the context of each of the antigens, as well as in the context of all possible sequential selection scenarios, where the selecting antigen can change. We focus on scenarios involving the two antigens that the donor was likely exposed to (<xref ref-type="fig" rid="fig5">Figure 5</xref>) – MA90 early in their life and SI06 later in their life – but we also perform this analysis with the MA90-G189E data (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Additionally, we consider selection resulting from a mixture of antigens, which we approximate by randomly selecting an antigen for each mutational step (<xref ref-type="bibr" rid="bib89">Wang et al., 2015</xref>) and average this pathway likelihood over 1000 random draws.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Antigen selection scenarios and likely mutational pathways.</title><p>(<bold>A</bold>) Selection scenario likelihood. Total log probability (in arbitrary units) of all mutational paths from the unmutated common ancestor (UCA) to CH65 (left) or paths from the UCA to CH65 that pass through I-2 (right), assuming specific antigen selection scenarios are shown. 'Most likely' scenarios are those with the highest total probability; 'various orders' show the most likely scenarios for scenarios that begin with MA90 and alternatively, with SI06. Error bars indicate standard error obtained through bootstrap, see 'Materials and methods.' (<bold>B</bold>) -log<italic>K</italic><sub>D</sub> for 25 most likely paths under designated antigen selection scenarios are shown with (right) and without (left) the constraint of passing through I-2. (<bold>C</bold>) Probability of each mutation occurring at a specific order under select antigen selection scenarios, with (right) and without (left) the constraint of passing through I-2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Antigen selection scenarios and likely mutational pathways with MA90, SI06, and MA90-G189E.</title><p>(<bold>A</bold>) Selection scenario likelihood. Total log probability (in arbitrary units) of all mutational paths from the unmutated common ancestor (UCA) to CH65 (left) or paths from the UCA to CH65 that pass through I-2 (right), assuming specific antigen selection scenarios are shown. 'Most likely' scenarios are those with the highest total probability; 'various orders' show the most likely scenarios for all possible orders of antigen exposure. Error bars indicate standard error obtained through bootstrap; see 'Materials and methods.' (<bold>B</bold>) -log<italic>K</italic><sub>D</sub> for 25 most likely paths under designated antigen selection scenarios are shown with (right) and without (left) the constraint of passing through I-2. (<bold>C</bold>) Probability of each mutation occurring at a specific order under select antigen selection scenarios, with (right) and without (left) the constraint of passing through I-2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Likelihood of passing through specific 3-mutation intermediates.</title><p>Histogram indicates number of 3-mutation variants with a given log-likelihood under the unconstrained moderate selection model presented in <xref ref-type="fig" rid="fig5">Figure 5</xref>. The log-likelihood corresponding to I-2, the expectation for a 3-mutation genotype chosen at random (1/560), and the median across all 3-mutation genotypes are indicated as vertical lines on the plot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig5-figsupp2-v3.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Graphical model for acquisition of antibody breadth.</title><p>(<bold>A</bold>) Hierarchical mutations confer affinity to two distinct antigens. In this model, mutations a and b (m<sub>x</sub>) improve affinity to antigen-1; mutations a, b, c, and d improve affinity to antigen-2 (m<sub>t</sub>). (<bold>B</bold>) Mutations may confer affinity additively or epistatically. Given the hierarchical structure of mutational effects defined in (<bold>A</bold>), affinity to each antigen could theoretically be mediated by additive (top) and/or epistatic (bottom) effects. (<bold>C</bold>) Additive and epistatic models result in distinct sequence-affinity landscapes. The hypothetical additive and epistatic mutational effects presented in (<bold>C</bold>) would result in distinct sequence-affinity landscapes (compare with data in <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Each point in the scatter plot represents one of the 16 possible genotypes, colored by the number of mutations it contains. (<bold>D</bold>) Graphical summary for epistasis-mediated breadth of CH65. The unmutated common ancestor (UCA) has affinity to MA90 and improves in affinity to MA90 through minimal mutations that are largely additive and low-order effects mediated by contacts with the antigen and HCDR3. After acquiring these mutations (m<sub>x</sub>), affinity to MA90 does not improve substantially, but additional mutations begin to improve affinity to SI06 through high-order synergistic epistasis mediated by multi-residue interactions.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83628-fig5-figsupp3-v3.tif"/></fig></fig-group><p>This pathway likelihood inference reveals that mutational trajectories leading to CH65 are most favorable in sequential selection scenarios that begin with MA90 and end with SI06, consistent with the donor’s likely exposure history (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). This order is preferred regardless of whether paths are constrained to pass through I-2 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Further, the MA90-SI06 sequential scenarios are considerably more likely than either antigen alone, a mixture of antigens, or SI06-MA90 sequential scenarios.</p><p>These drastic differences in scenario likelihood result from the effects of specific mutations on various genetic backgrounds. Mutations on the UCA background can improve affinity to MA90 but not to SI06, so MA90 is favored as the selecting antigen initially. After a few mutations, however, MA90 reaches maximal affinity and cannot improve further, at which point mutations begin to improve SI06 affinity. Thus, SI06 is favored later in mutational trajectories (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These constraints reflect the structure of the sequence-affinity landscape: selection with MA90 favors mutations that enable the acquisition of SI06 affinity and would be unlikely to occur under selection with SI06 alone. Similarly, when we consider all three antigens, we find that scenarios that begin with MA90 or MA90-G189E and end with SI06 are most likely, again reflecting the hierarchical nature of the sequence-affinity landscape (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><p>We also leverage our combinatorial data to infer the probability of each mutation occurring at a given step along the evolutionary pathway from UCA to CH65 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Even when we do not constrain pathways to pass through I-2, we find that two of the I-2 mutations (G31D and N52H) and the epistatic mutations that interact with the HCDR3 (e.g<italic>.,</italic> Y33H, H35N, and the previously uncharacterized Y35N) are most likely to occur early in mutational trajectories, especially in scenarios that begin with MA90 selection. Additionally, the highly synergistic HCDR3-stabilizing mutations Y48C and D49Y are most likely to occur late, and consecutively, with D49Y preceding the otherwise-deleterious Y48C. These general trends are robust to constraining paths to pass through the I-2 intermediate. Consistent with our structural analyses, we find that when pathways are constrained to pass through I-2, Y35N is the most probable subsequent mutation, and this likelihood rapidly decreases with additional mutations. However, when we consider all possible pathways in the optimal antigen selection scenario, I-2 is not the most likely 3-mutation intermediate, suggesting that the evolution of CH65 was not contingent on passing through I-2 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Still, the likelihood of passing through the I-2 intermediate is ~55% higher than that expected by chance – it is a minimally mutated antibody with improved affinity to MA90 and MA90-G189E, and it contains the N52H mutation that is essential for SI06 affinity. Thus, while there are many accessible paths to CH65, the three mutations in I-2 result in rapid improvements in affinity and breadth and favor subsequent selection for epistatic mutations that ultimately provide the breadth of CH65.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Collectively, we find that the breadth of an RBS influenza bnAb, CH65, is determined by high-order epistatic interactions that differ between divergent antigens (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). This epistasis is widespread within and between both the heavy and light chains. To our knowledge, this is the first comprehensive study of inter-chain epistasis and illustrates the extent to which mutations can differentially impact affinity depending on the presence of other mutations, even those too far apart to physically interact. This suggests that the maturation of antibodies that engage antigen with both chains may be distinct compared to those that do not. There are more opportunities for epistatic interactions across two chains compared to just one, and the degree of both intra- and inter-chain epistasis is likely contingent on the chain pairing. Given the importance of both light and heavy chain mutations across diverse bnAbs (<xref ref-type="bibr" rid="bib18">Corti et al., 2011</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>; <xref ref-type="bibr" rid="bib97">Xiao et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Ekiert and Wilson, 2012</xref>), understanding the nature of this epistasis may be useful for designing therapeutic antibodies and eliciting broadly protective immune responses.</p><p>Further, our structural analysis shows that the epistasis that confers broad reactivity in this antibody is mediated through sets of mutations that both interact with HA and those that do not interact with HA. These epistatic mutations add or remove interactions between CDRs, FWRs, and chains that act by different mechanisms of stabilizing the binding conformation (e.g<italic>.,</italic> G31D and N52H) or removing constraints on the HCDR3 (e.g<italic>.,</italic> Y35N and H35N). The Y35N mutation effectively removes interactions between the LFWR2 and the HCDR3 at the V<sub>H</sub>-V<sub>L</sub> interface and mediates affinity improvement to a more antigenically advanced influenza strain by increasing the association rate. An analogous observation was noted for the anti-HIV bnAb CH103 that co-evolved during a natural infection within in a single individual (<xref ref-type="bibr" rid="bib53">Liao et al., 2013</xref>). Structural studies of CH103 identified mutations at the V<sub>H</sub>-V<sub>L</sub> interface (which is the region containing residue 35 in CH65) that were associated with reconfiguration of the HCDR3 to enable broad reactivity against a viral escape variant (<xref ref-type="bibr" rid="bib30">Fera et al., 2014</xref>). Although additional work will be needed to address the generality of this finding, it appears that antibodies can evolve to bind viral escape variants by modulating the V<sub>H</sub>-V<sub>L</sub> interface and the HCDR3 configuration, in response to both chronic (HIV) and punctuated (influenza) exposures. While Y35N is advantageous early in affinity maturation, it becomes detrimental in highly mutated backgrounds that have undergone HCDR3 rigidification. Consequently, Y35N may function to initially increase flexibility, enabling acquisition of affinity to SI06 after acquiring mutations in the heavy chain, and subsequent maturation rigidified the HCDR3. This increased flexibility followed by rigidification is reminiscent of molecular dynamics studies of anti-HIV bnAbs that suggest initial increases in flexibility may provide a means to sample additional conformational space prior to rigidification (<xref ref-type="bibr" rid="bib66">Ovchinnikov et al., 2018</xref>).</p><p>In comparing CH65 mutations that improve affinity to diverse H1 antigens, we find that increasingly divergent antigens require additional epistatically interacting mutations, resulting in a hierarchical pattern of mutations that improve affinity to distinct antigens. The I-2 mutations (e.g<italic>.,</italic> G31D, M34I, N52H) may compensate for the G189E mutation by stabilizing interactions with HA opposite this site, potentially allowing the antibody to shift to relieve the clash; a similar observation was made for another RBS-directed antibody (<xref ref-type="bibr" rid="bib56">McCarthy et al., 2019</xref>). These same mutations help to stabilize binding in the antigenically distant SI06 but do not sufficiently compensate for the loss of potential contacts between the HCDR3 and the RBS (e.g<italic>.,</italic> ∆K133a and E156G) within the antigen combining site; further mutations Y35N and H35N that likely influence HCDR3 conformations are needed. These structural observations and the data generated here suggest that mutations confer broad reactivity in the CH65 lineage in a hierarchical manner. Although the hierarchical landscape of CH65 is not as striking as that of CR9114 (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>), where larger sets of mutations are required to bind substantially more divergent antigens, it is intriguing that the landscape for a considerably narrower bnAb can also have this structure. This suggests that hierarchical sequence-affinity landscapes may be quite common, as they are not unique to CR9114, to anti-stem bnAbs, or to bnAbs that engage distinct HA subtypes.</p><p>If hierarchical sequence-affinity landscapes are common amongst bnAbs, they may contribute to the low frequencies of bnAbs in human repertoires. For bnAbs with such landscapes, epistatically interacting mutations are required to bind a given antigen, additional epistatic mutations (that interact favorably with those acquired previously) are required to bind a distinct antigen, and so on. Determining how this might constrain bnAb evolution will require assessing how rare these sets of synergistic mutations are. Importantly, the landscapes measured here and in our previous work focus exclusively on mutations present in the affinity-matured antibodies, which are biased by the selection pressures those bnAbs experienced. Thus, while these landscapes show that diverse bnAbs can mature by acquiring hierarchical sets of epistatic mutations that are favored in sequential exposure regimens, there may be alternative mutational pathways to breadth that are not hierarchical and are favored in other exposure regimes.</p><p>Still, the observation that antibodies <italic>can</italic> evolve breadth through hierarchical mutational landscapes lends support for vaccination with sequential doses of distinct antigens. These findings are consistent with a recent study that demonstrates memory B cell recruitment to secondary germinal centers upon vaccination in humans, allowing for additional rounds of antibody maturation to antigenically drifted strains (<xref ref-type="bibr" rid="bib84">Turner et al., 2020</xref>). Here, we find that sequential exposures with antigenically drifted strains may help elicit within-subtype potent bnAbs like CH65, in addition to the cross-subtype bnAbs described in our previous work. Several theoretical and computational models of bnAb affinity maturation also favor sequential immunization strategies as they allow antibodies to acquire the mutations necessary to bind one antigen before experiencing selection pressure to bind another, ultimately producing bnAbs that have ‘focused’ on conserved epitopes (<xref ref-type="bibr" rid="bib89">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Sachdeva et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Wang, 2017</xref>; <xref ref-type="bibr" rid="bib59">Molari et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Sprenger et al., 2020</xref>). Our work indicates that this focusing process may occur by favoring selection on hierarchical sets of epistatically interacting mutations. We note that while the hierarchical epistasis we observe favors the acquisition of breadth to a set of specific antigens, antagonistic epistasis between these mutations and new mutations could prevent the acquisition of breadth to other antigens. Further, both CH65 and CR9114 have higher affinity to the strain most like the inferred original immunogenic stimulus, and weaker affinity to more divergent strains (<xref ref-type="bibr" rid="bib23">Dreyfus et al., 2012</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). This is consistent with the concept of immunological imprinting or original antigenic sin, where antibodies boosted upon vaccination or infection typically have high affinity for the eliciting strain (<xref ref-type="bibr" rid="bib36">Guthmiller and Wilson, 2018</xref>). Although we show that the CH65 antibody lineage can evolve breadth that compensates for viral escape mutations, the affinities are lower for more antigenically distant strains, suggesting that there is likely a trade-off between antibody breadth and affinity. Further work will be needed to assess whether RBS-targeting bnAbs like CH65, which target highly variable epitopes compared to stem-targeting bnAbs (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>; <xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>), can mature to bind substantially divergent strains (e.g<italic>.,</italic> post-pandemic H1N1 strains that CH65 does not effectively neutralize), or whether historical contingency prevents them from doing so.</p><p>Finally, although epistasis can make evolution more difficult to predict (<xref ref-type="bibr" rid="bib21">de Visser et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Park et al., 2022</xref>), the general patterns of epistasis emerging from these combinatorial landscapes suggest that there are indeed broadly applicable insights. For example, these hierarchical synergistic interactions reveal how epistasis constrains the evolution of antibody affinity, breadth, and trade-offs between the two. Moving forward, additional combinatorial antibody libraries will advance our understanding of how pervasive these features are – for example, for antibodies that target distinct viruses. Ultimately, though, to understand why we observe these particular bnAbs and not others, we need to explore the unobserved regions of sequence space. We also need to assess the numerous other properties that likely impact selection on antibodies (e.g<italic>.,</italic> stability, folding, polyreactivity). Thus, integrating approaches like this combinatorial approach with methods for assessing local mutational landscapes (e.g<italic>.,</italic> deep mutational scanning) and methods to measure other antibody properties in high throughput will provide a more comprehensive view of the factors that constrain and potentiate antibody evolution.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Saccharomyces cerevisiae</italic>)</td><td align="left" valign="bottom">EBY100</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# MYA-4941</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (influenza A virus)</td><td align="left" valign="bottom">Influenza A/Puerto Rico/8/1934 with A/Massachusetts/1/1990HA and A/Siena/10/1989 NA</td><td align="left" valign="bottom">Jesse Bloom and this paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">GenBank: L19027 (HA); GenBank: CY036823 (NA)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Canis lupus familiaris</italic>)</td><td align="left" valign="bottom">MDCK-SIAT1</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# 05071502</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Expi293F</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# A14527</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-cMyc-FITC<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-116-485</td><td align="left" valign="bottom">FACS (1:50)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCHA (plasmid)</td><td align="left" valign="bottom">Dane Wittrup <xref ref-type="bibr" rid="bib55">Mata-Fink et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCHA_UCA860_scFv (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Plasmid map in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCHA_CH65_scFv (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Plasmid map in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CH65 golden gate primers</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequences listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Illumina sequencing primers</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequences listed in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Streptavidin-RPE</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# S866</td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">A/Massachusetts/1/1990 – MA90</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequence in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">A/Massachusetts/1/1990 – MA90-G189E</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequence in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">A/Solomon Islands/03/2006</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Sequence in <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Various Fabs &amp; IgGs</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> for specific sequences</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BirA500 kit</td><td align="left" valign="bottom">Avidity</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Zymo Yeast Plasmid Miniprep II</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# D2004</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Custom code</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/amphilli/CH65-comblib">github.com/amphilli/CH65-comblib</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Interactive data browser</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://ch65-ma90-browser.netlify.app/">https://ch65-ma90-browser.netlify.app/</ext-link></td></tr></tbody></table></table-wrap><p>For all methods, ‘biological replicates’ refer to independent experiments performed on different days, and ‘technical replicates’ refer to multiple measurements of the same biological sample.</p><sec id="s4-1"><title>Antibody library production</title><sec id="s4-1-1"><title>Antibody sequences and mutations of interest</title><p>The UCA860 amino acid sequence (<xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>) was codon-optimized for expression in yeast. Amino acid substitutions corresponding to those in CH65 were encoded by ≥2 nucleotide mutations, when possible. The V98I mutation, which lies outside the region captured by 2 × 250 bp reads, was encoded by a synonymous mutation at Arg53. The Q1E and S75A mutations in V<sub>H</sub> were determined to minimally influence affinity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and were excluded from all subsequent experiments to reduce the library size.</p></sec><sec id="s4-1-2"><title>Yeast display plasmid and strains</title><p>Single-chain variable format (scFv) antibody constructs were cloned via Gibson Assembly (<xref ref-type="bibr" rid="bib33">Gibson et al., 2009</xref>) into the pCHA yeast display vector (<xref ref-type="bibr" rid="bib87">Van Deventer et al., 2015</xref>) with a C-terminal myc epitope tag and Aga-2 fusion (<xref ref-type="supplementary-material" rid="supp1 supp2">Supplementary files 1 and 2</xref>). These scFv constructs were displayed on the surface of the EBY100 yeast strain (<xref ref-type="bibr" rid="bib11">Boder and Wittrup, 1997</xref>), as described below for the yeast library production. Unless otherwise noted, yeast were cultured by rotating at 30°C and were pelleted by centrifuging at 14,000 × <italic>g</italic> (1 min) or 3000 × <italic>g</italic> (10 min).</p></sec><sec id="s4-1-3"><title>Combinatorial Golden Gate Assembly</title><p>To assemble the combinatorially complete library containing all 2<sup>16</sup> = 65,536 variants, the scFv sequence was sectioned into five fragments of roughly equal length such that each fragment contained ≤5 mutations. Primers were designed to create all possible (≤2<sup>5</sup>) versions of each fragment by adding mutations, a Bsa-I cleavage site, and a 4 bp overhang unique to each fragment (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Fragments were amplified from the UCA860 sequence via PCR using Q5 Polymerase (NEB, Ipswich, MA, #M0491). The resulting fragments were purified using a 2× ratio of Aline beads (Aline Biosciences, Woburn, MA, #C-1003-5), overnight DpnI digestion at 37°C (NEB #R0176), and a second 2× ratio bead cleanup. The backbone vector was prepared by replacing the scFv sequence in the pCHA yeast display vector with a <italic>ccdb</italic> counter-selection marker. Equimolar amounts of each fragment were then pooled and assembled into the backbone vector at a 2:1 molar ratio via Golden Gate Assembly (<xref ref-type="bibr" rid="bib29">Engler et al., 2008</xref>; NEB #R3733). The assembly mix was then transformed into electrocompetent DH10B <italic>Escherichia coli</italic> in 5 × 25 uL cell aliquots (NEB #C3020). Each cell aliquot was recovered in 1 mL outgrowth media at 37°C for 1 hr and then transferred into 100 mL of molten LB (1% tryptone, 0.5% yeast extract, 1% NaCl, 100 g/L ampicillin [VWR # V0339], 0.4% SeaPrep agarose [VWR, Radnor, PA #12001-922]) in a 500 mL baffled flask. The bacteria–agar mixture was incubated at 4°C for 3 hr to gel the agar and was then incubated at 37°C for 16 hr. Each flask contained 1–2 million colonies (5–10 million colonies across five flasks; &gt;100 times the library diversity) and was blended by shaking at 200 rpm for 1 hr. The cells were then pelleted by spinning at 3000 × <italic>g</italic> for 10 min, and plasmid DNA was extracted using the ZymoPURE II Plasmid Midiprep Kit (Zymo Research, Irvine, CA, #D4201).</p></sec><sec id="s4-1-4"><title>Yeast library production</title><p>One day prior to transformation, EBY100 cells were thawed by inoculating 5 mL YPD (1% Bacto yeast extract [VWR #90000-726], 2% Bacto peptone [VWR #90000-368], 2% dextrose [VWR #90000-904]) with 150 µL glycerol stock and rocking at 30°C for 12–24 hr. The scFv plasmid library was then transformed into EBY100 cells by the lithium acetate method (<xref ref-type="bibr" rid="bib34">Gietz and Schiestl, 2007</xref>) and transformants were recovered in 100 mL molten SDCAA (1.71 g/L YNB without amino acids and ammonium sulfate [Sigma-Aldrich, St. Louis, MO, #Y1251], 5 g/L ammonium sulfate [Sigma-Aldrich #A4418], 2% dextrose [VWR #90000-904], 5 g/L Bacto casamino acids [VWR #223050], 100 g/L ampicillin [VWR # V0339], 0.4% SeaPrep agarose [VWR #12001-922]) in 500 mL baffled flasks. The yeast–agar mixture was incubated at 4°C for 3 hr to allow the agar to set and was then incubated at 30°C for 48 hr to allow for yeast colony growth. Each flask contained ~700,000 colonies, totaling about 7 million colonies across ten flasks (&gt;100 times the library diversity). After disrupting the agar by shaking at 200 rpm for 1 hr, the yeast library was inoculated into liquid SDCAA (1.71 g/L YNB without amino acids and ammonium sulfate [Sigma-Aldrich #Y1251], 5 g/L ammonium sulfate [Sigma-Aldrich, #A4418], 2% dextrose [VWR #90000-904], 5 g/L Bacto casamino acids [VWR #223050], 100 g/L ampicillin [VWR # V0339], 5.4 g Na<sub>2</sub>HPO<sub>4</sub> [Sigma-Aldrich, #S7907], 8.56 g NaH<sub>2</sub>PO<sub>4</sub>.H<sub>2</sub>O [Sigma-Aldrich, #S9638]) (<xref ref-type="bibr" rid="bib15">Chao et al., 2006</xref>) and grown for five generations to saturation before freezing at –80°C in 1 mL aliquots containing 5% glycerol.</p></sec></sec><sec id="s4-2"><title>Viral escape</title><sec id="s4-2-1"><title>Cell lines and media</title><p>HEK293T cells (ATCC #CRL-3216; authenticated by STR profiling and verified mycoplasma-negative by manufacturer) were passaged in DMEM (Gibco, #11965126) supplemented with 10% fetal bovine serum (Peak Serum) and Penicillin-Streptomycin (Gibco, #15140163) subsequently referred to as 'D10.' MDCK-SIAT1 cells (Sigma, #05071502; authenticated by STR profiling and verified mycoplasma-negative by manufacturer) were passaged in D10 additionally supplemented with 1 mg/ml Geneticin (Gibco, #10131035). Prior to infection, Geneticin was not included in the MDCK-SIAT1 medium. Media used to propagate influenza, referred to as 'flu media,' contain Opti-MEM (Gibco, #31985088) supplemented with 0.3% BSA (Roche, #03117332001), 0.01% FBS, and Penicillin-Streptomycin. Prior to propagation, 1 µg/mL of TPCK-trypsin (Sigma, #T1426) was freshly added to flu media.</p></sec><sec id="s4-2-2"><title>Generation of recombinant MA90 virus</title><p>We used a standard eight plasmid reverse genetics system (<xref ref-type="bibr" rid="bib41">Hoffmann et al., 2000</xref>) to generate a recombinant 6:2 virus bearing the PB2, PB1, PA, NP, M, and NS genomic segments from PR8 (A/Puerto Rico/8/1934; a kind gift from Jesse Bloom), MA90 HA (GenBank: L19027), and A/Siena/10/1989 NA (GenBank: CY036825). Because the sequencing of the MA90 HA was not complete, the C-terminus was extended with that of A/Siena/10/1989 (GenBank: CY036823). In a six-well plate treated with poly-L-lysine (Sigma, #P4707), 6 × 10<sup>5</sup> HEK293T cells and 1 × 10<sup>5</sup> MDCK-SIAT1 cells were added to wells six-well plates in D10. The next day, media was aspirated from the cells and fresh, pre-warmed D10 was added on top. For each transfection, 8 µL of Trans-IT LT1 (Mirus, #2300) was added to Opti-MEM (Gibco, #31985070) containing 0.5 µg of each plasmid and incubated at room temperature for 20 min. The mixture was then added dropwise to the cells. After ~5 hr, the media was aspirated from the cells and flu media freshly supplemented with 1 µg/mL TPCK-treated trypsin was added. After 2 days, dead cells were removed from the virus-containing media by centrifugation at 800 × <italic>g</italic> for 5 min. The supernatant was then supplemented with 1 µg/mL TPCK-treated trypsin and added to a confluent monolayer of MDCK-SIAT1 cells seeded 1 day before in a six-well plate and washed once with PBS (seeded at 7 × 10<sup>5</sup> cells per well). After ~4–5 hr, the supernatant was removed, and fresh flu media supplemented with 1 µg/mL TPCK-treated trypsin was added. One day later, successful rescue was judged by observing cytopathic effect. Multiple rescue transfections were pooled and added to 10 cm dishes containing a confluent monolayer of MDCK-SIAT1 cells seeded 1 day prior (at 3 × 10<sup>6</sup> cells per dish) as detailed above. Two days later, successful propagation was judged by cytopathic effect, the supernatant was clarified by centrifugation, and aliquots were frozen at –80°C.</p></sec><sec id="s4-2-3"><title>Escape variant generation</title><p>Prior to infection, MA90 virus was incubated with a low concentration of antibody (started at 0.01 µg/mL of the UCA), a higher concentration of antibody (one half-log greater than the lower concentration), or no antibody (as a control for cell line adaptation mutations) in 500 µL of flu media supplemented with 1 µg/mL TPCK-treated trypsin for 1 hr at 37°C and 5% CO<sub>2</sub>. MDCK-SIAT1 cells seeded the day before were washed with PBS and then virus–antibody mixtures were added to the monolayers and incubated for 1 hr at 37°C and 5% CO<sub>2</sub>, rocking the plate every ~15 min to ensure that the cells did not dry out. Afterward, the viral inoculum was removed, and the cells were washed with PBS before adding fresh flu media supplemented with 1 µg/mL TPCK-treated trypsin. After 2 days, viral growth was judged by cytopathic effect. The well that grew with a higher concentration of antibody was selected for the next passage where the 'low' antibody concentration was the same as the previous passage and the 'high' concentration was a half-log higher. This process was repeated until viral growth was readily detectable at 100 µg/mL of the UCA. If necessary, a hemagglutination assay using turkey red blood cells (Lampire, #7249409) was run to determine whether virus was present. Briefly, twofold dilutions of the virus in PBS were mixed with 0.5% turkey red blood cells and incubated at room temperature for at least 30–45 min before visualization of red blood cell pellets to determine whether virus had grown significantly. Once the virus still grew in 100 µg/mL of the antibody, the virus was passaged one additional time and 100 µg/mL of antibody was additionally added to the media added after infection. The RNA from the escaped virus was isolated using a QIAamp viral RNA mini kit (QIAGEN, #52904), and the full-length HA was amplified using gene-specific primers and the OneStep RT-PCR kit (QIAGEN, #210212). The resulting PCR product was sequenced by Sanger sequencing (Genewiz). The mutation G189E was identified from the sequencing results and produced as a recombinant protein for subsequent experiments (see below).</p></sec></sec><sec id="s4-3"><title>Antigen and IgG production</title><sec id="s4-3-1"><title>Choice of HA antigens</title><p>Antibodies CH65, CH66, and CH67 were isolated from plasmablasts from donor TIV01 (<xref ref-type="bibr" rid="bib60">Moody et al., 2011</xref>) after receiving the trivalent influenza vaccine in the 2007–2008 influenza season, which contained the A/Solomon Islands/3/2006 (SI06) H1N1 strain. The donor TIV01 was born in ~1990 and subsequent work identified that the inferred UCA of this lineage bound to the strain A/Massachusetts/1/1990 (MA90) circulating near the donor’s birth date and is suspected to be highly similar to the original immunogenic stimulus of this lineage (<xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). However, the UCA did not bind SI06, which escaped the UCA and I-2 of this lineage (<xref ref-type="bibr" rid="bib78">Schmidt et al., 2015a</xref>). To assess whether affinity maturation in this lineage is capable of accommodating for an escape mutation that abrogates binding to less mature variants, we drove viral escape from MA90 in vitro (see above) using the UCA and identified that matured variants of this lineage (e.g., CH65 and CH67) bound the escape variant (MA90-G189E) with high affinity. To understand how this antibody lineage evolved to compensate for viral escape mutations, we included MA90-G189E and SI06 in addition to MA90.</p></sec><sec id="s4-3-2"><title>Recombinant protein cloning, expression, and purification</title><p>Variable heavy and light chains were synthesized as eBlocks (IDT). Full-length, codon-optimized HAs (A/Massachusetts/1/1990 – MA90 [<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>], MA90-G189E [<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>], and A/Solomon Islands/03/2006 – SI06 [<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>]) and full-length human IgG1 heavy and light chains were cloned into a pVRC expression vector containing a C-terminal HRV 3C cleavage site, His tag, FoldOn trimerization domain, and AviTag for HAs and a HRV 3C cleavage site followed by a C-terminal His tag for antibody heavy chains. Recombinant proteins were produced in Expi293F cells (Gibco, #A14527; authenticated by STR profiling and verified mycoplasma-negative by the manufacturer) following the manufacturer’s directions. The trimeric HAs were purified from the supernatant using TALON metal affinity resin (Takara, #635653), washing with PBS, and eluting with PBS containing 200 mM imidazole (pH 7.4). After concentration, proteins were further purified over an S200 column on an AKTA pure (Cytiva). For yeast surface display assays, the HAs were further biotinylated and flash-frozen in liquid nitrogen (see below). For kinetics measurements, the HAs were used within 2 weeks of production and never frozen.</p></sec><sec id="s4-3-3"><title>HA biotinylation</title><p>Biotinylation of the HAs was performed using the BirA500 kit (Avidity) following the manufacturer’s instructions. To compensate for the reduced activity in PBS, twice the amount of BirA was added and the reaction was additionally supplied with twice the amount of biotin using the supplied BIO-200. The biotinylation reaction was allowed to proceed for 1.5 hr at 30°C before 0.2 µm filtering and purification over an S200 column (Cytiva). The trimeric HAs were then concentrated and flash-frozen in liquid nitrogen for single-use aliquots. Biotinylated HAs were quality controlled by a gel shift assay. Approximately 2 µg of biotinylated HA was heated in non-reducing Laemmli buffer (Bio-Rad, #1610737) at 95°C for 5 min. Once cooled to room temperature, excess streptavidin was added and allowed to incubate for at least 5 min. As a control, samples were run with PBS added rather than streptavidin. The mixture was then run on a Mini-PROTEAN TGX Stain-Free gel (Bio-Rad, #4568096) and imaged. All biotinylated HAs shifted in the presence of streptavidin, indicating successful biotinylation.</p></sec></sec><sec id="s4-4"><title>Tite-Seq assays</title><p>Tite-Seq assays were performed in biological duplicate (on different days) for each antigen, as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Adams et al., 2016</xref>) with some modifications described below.</p><sec id="s4-4-1"><title>Induction of antibody expression</title><p>On day 1, the yeast CH65 library and isogenic strains containing the pCHA-UCA860 or pCHA-CH65 plasmids were thawed by inoculating 5 mL SDCAA with 150 µL glycerol stock and rotating at 30°C for 24 hr. On day 2, yeast cultures were back-diluted to OD600 = 0.2 in 5 mL SDCAA and rotated at 30°C until they reached an OD600 = 0.4–0.6 (about 4 hr). Subsequently, 1.5 mL of these log-phase cultures were pelleted, resuspended in 4 mL SGDCAA (1.71 g/L YNB without amino acids and ammonium sulfate [Sigma-Aldrich #Y1251], 5 g/L ammonium sulfate [Sigma-Aldrich, #A4418], 1.8% galactose [Sigma-Aldrich #G0625], 0.2% dextrose [VWR #90000-904], 5 g/L Bacto casamino acids [VWR #223050], 100 g/L ampicillin [VWR # V0339], 5.4 g Na<sub>2</sub>HPO<sub>4</sub> [Sigma-Aldrich, #S7907], 8.56 g NaH<sub>2</sub>PO<sub>4</sub>.H<sub>2</sub>O [Sigma-Aldrich, #S9638]) (<xref ref-type="bibr" rid="bib15">Chao et al., 2006</xref>), and rotated at room temperature for 20–22 hr.</p></sec><sec id="s4-4-2"><title>Primary antigen labeling</title><p>On day 3, following induction of scFv expression, cultures were pelleted, washed twice with cold 0.1% PBSA (VWR #45001-130, GoldBio, St. Louis, MO, #A-420-50), and resuspended to an OD600 of 1. For each concentration of antigen (0.75-log increments spanning 1 µM to 1 pM), 700 µL of the CH65 yeast library (OD600 = 1) were incubated with biotinylated HA by rocking at 4°C for 24 hr. Notably, the volume of each antigen concentration was adjusted such that the number of antigen molecules exceeded that of antibody molecules by at least tenfold (assuming 50,000 scFv/cell) (<xref ref-type="bibr" rid="bib11">Boder and Wittrup, 1997</xref>).</p></sec><sec id="s4-4-3"><title>Secondary fluorophore labeling</title><p>On day 4, yeast-HA complexes were pelleted at 4°C and washed twice with 5% PBSA + 2 mM EDTA. Complexes were then incubated with Streptavidin-RPE (1:100, Thermo Fisher Scientific, Waltham, MA, #S866) and anti-cMyc-FITC (1:50, Miltenyi Biotec, Somerville, MA, #130-116-485) at 4°C for 45 min in the dark. Following incubation, complexes were washed twice with 5% PBSA + 2 mM EDTA and stored on ice in the dark until sorting.</p></sec><sec id="s4-4-4"><title>Sorting</title><p>Yeast-HA complexes were sorted on a BD FACS Aria Illu equipped with an 85 micron fixed nozzle and 405 nm, 440 nm, 488 nm, 561 nm, and 635 nm lasers. Single-color controls were used to compensate for minimal overlap between the FITC and PE channels. For all sorts, single cells were gated by FSC vs SSC, and the resulting population was sorted either by expression (FITC) or HA binding (PE). For the expression sort, ~1.6 million (~20× library diversity) single cells were sorted into four gates of equal width spanning the FITC-A axis. For the HA binding sort, ~1.6 million scFv-expressing cells were sorted into four gates spanning the PE-A axis, with one gate capturing all PE-negative cells, and the remaining three each capturing 33% of the PE-positive cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). All cells were sorted into 5 mL polypropylene tubes containing 1 mL of 2× SDCAA supplemented with 1% BSA and were stored on ice until recovery.</p></sec><sec id="s4-4-5"><title>Recovery and plasmid extraction</title><p>Following sorting, yeast were pelleted by spinning at 3000 <italic>× g</italic> for 10 min at 4°C. Supernatant was carefully removed by pipette, and the resulting pellet was resuspended in 4 mL SDCAA and transferred to a glass culture tube. A small amount of this resuspension (targeting 200–500 cells, based on sorting counts) was plated on SDCAA-agar and YPD-agar to quantify recovery efficiency and plasmid loss. Cultures were then rocked at 30°C until reaching OD600 = 0.8–2.</p><p>After reaching the target OD600, 1.5 mL yeast culture was pelleted and frozen at –80°C for at least an hour. Plasmid was then extracted using the Zymo Yeast Plasmid Miniprep II kit (Zymo Research #D2004) following the manufacturer’s instructions, except for the following changes: 5 µL zymolyase was used per sample, zymolyase incubations were 2–3 hr, precipitate following neutralization was removed by centrifugation at 21,000 <italic>× g</italic> for 10 min, columns were washed using 650 µL wash buffer and dried by spinning at 16,000 <italic>× g</italic> for 3 min, and plasmid was eluted in 15 µL elution buffer.</p></sec><sec id="s4-4-6"><title>Sequencing library preparation</title><p>ScFv amplicon sequencing libraries were then prepared by a two-step PCR as previously described (<xref ref-type="bibr" rid="bib64">Nguyen Ba et al., 2019</xref>). The first PCR appended unique molecular identifiers (UMI), sample-specific inline indices, and a partial Illumina adapter to the scFv sequence, and was performed for five cycles to minimize PCR amplification bias. The second PCR appended the remainder of the Illumina adapter and sample-specific Illumina i5 and i7 indices, and was performed for 35 cycles to produce a sufficient amount of each amplicon library (primer sequences in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). The first PCR used 5 µL plasmid DNA as template for a 20 µL reaction using Q5 polymerase according to the manufacturer’s instructions with the following cycling program: (1) 60 s at 98°C, (2) 10 s at 98°C, (3) 30 s at 67°C, (4) 60 s at 72°C, (5) GOTO 2, 4<italic>×</italic>, and (6) 60 s at 72°C. The product from PCR 1 was then brought up to 40 µL with MBG water, purified using Aline beads at a ratio of 1.2<italic>×</italic>, and eluted in 35 µL elution buffer. 33 µL of this elution was used as template for the second PCR, which was a 50 µL reaction using Kapa polymerase (Kapa Biosystems, Wilmington, MA, #K2502) as per the manufacturer’s instructions and the following cycling program: (1) 30 s at 98°C, (2) 20 s at 98°C, (3) 30 s at 62°C, (4) 30 s at 72°C, (5) GOTO 2, 34<italic>×</italic>, and (6) 300 s at 72°C. The resulting amplicons were purified using Aline beads at a ratio of 0.85<italic>×</italic>, and DNA concentration was determined using a fluorescent DNA-binding dye (Biotum, Fremont, CA, #31068) as per the manufacturer’s instructions. Amplicons were then pooled amongst the four bins for each concentration, based on the number of cells sorted into each gate, and then equimolar amounts of the resulting pools were combined to make the final pooled library. Prior to sequencing, the pool concentration was determined by Qubit and the size verified by Tapestation HS DNA 5000 and 1000. The pool was then sequenced on a NovaSeq SP (2x250 paired-end reads) with 10% PhiX spike-in; 2–4 curves were loaded onto a single flow cell to sequence each variant at at least 100<italic>×</italic> coverage.</p></sec><sec id="s4-4-7"><title>Sequencing data processing</title><p>Demultiplexed sequencing reads were parsed using a Snakemake pipeline as previously described (<xref ref-type="bibr" rid="bib61">Moulana et al., 2022</xref>) (see <ext-link ext-link-type="uri" xlink:href="https://github.com/amphilli/CH65-comblib">github.com/amphilli/CH65-comblib</ext-link> for parameters). Briefly, UMI, inline indices, and genotypes were extracted from each read using (<xref ref-type="bibr" rid="bib32">Friedl, 2009</xref>). Reads with incorrectly paired inline indices or unexpected mutations at the CH65 mutation sites were discarded. In all other regions of the read, all reads exceeding a 10% error rate were discarded. Following this filtering, reads were deduplicated by UMI to generate unique counts files for each sample.</p></sec></sec><sec id="s4-5"><title>Tite-Seq <italic>K</italic><sub>D</sub> inference</title><sec id="s4-5-1"><title>Mean-bin approach</title><p>To fit the dissociation constant (<italic>K</italic><sub>D</sub>) for each variant in the library, we followed the same method as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). Briefly, we use the sequencing counts and flow cytometry data to infer the mean log-fluorescence of each genotype <italic>s</italic> at each concentration <italic>c</italic>:<disp-formula id="equ1"><mml:math id="m1"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>̄</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <italic>F<sub>b,c</sub></italic> is the mean log-fluorescence of bin <italic>b</italic> at concentration <italic>c</italic>, and <italic>p<sub>b,s|c</sub></italic> is the proportion of cells with genotype <italic>s</italic> sorted into bin <italic>b</italic> at concentration <italic>c</italic>, and is given by:<disp-formula id="equ2"><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>where <italic>R<sub>b,s,c</sub></italic> is the number of reads with genotype <italic>s</italic> found in bin <italic>b</italic> at concentration <italic>c</italic>, and <italic>c<sub>b,c</sub></italic> is the number of cells sorted into bin <italic>b</italic> at concentration <italic>c</italic>.</p><p>Uncertainty is then propagated in these mean bin estimate as:<disp-formula id="equ3"><mml:math id="m3"><mml:mi>δ</mml:mi><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>̄</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi> </mml:mi><mml:mi>δ</mml:mi><mml:msubsup><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mi>δ</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:msqrt></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf2"><mml:mi>δ</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the standard deviation of log-fluorescence for cells sorted into bin <italic>b</italic> at concentration <italic>c</italic>. This is approximated by <inline-formula><mml:math id="inf3"><mml:mi>σ</mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and the error in <italic>p<sub>b,s|c</sub></italic> results from sampling error, which is approximated as a Poisson process at sufficient sequencing coverage, yielding:<disp-formula id="equ4"><mml:math id="m4"><mml:mi>δ</mml:mi><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>|</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msqrt><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:msqrt></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>The dissociation constant, <italic>K<sub>D,s</sub></italic>, was inferred for each genotype by fitting the logarithm of the Hill function to the mean log-fluorescence:<disp-formula id="equ5"><mml:math id="m5"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>̄</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi> </mml:mi></mml:mrow></mml:msub></mml:math></disp-formula></p><p>where <italic>A<sub>s</sub></italic> is the increase in fluorescence at antigen saturation and <italic>B<sub>s</sub></italic> is the background fluorescence in the absence of antigen. The fit was performed using the Python package <italic>scipy.optimize curve_fit</italic> function using the following boundary conditions: <italic>A<sub>s</sub></italic> (10<sup>2</sup> – 10<sup>6</sup>), <italic>B<sub>s</sub></italic> (1 – 10<sup>5</sup>), <italic>K<sub>D,s</sub></italic> (10<sup>–14</sup> – 10<sup>–5</sup>).</p></sec><sec id="s4-5-2"><title>Data quality and filtering</title><p>Following the <italic>K<sub>D,s</sub></italic> inference, non-binding sequences with <italic>K<sub>D,s</sub></italic>&lt;6 or <italic>A<sub>s</sub> – B<sub>s</sub></italic> &lt;1 were pinned to the titration boundary with -log<italic>K<sub>D,s</sub></italic> = 6. Subsequently, <italic>K<sub>D,s</sub></italic> values resulting from poor fits (r<sup>2</sup> &lt; 0.8, σ &gt; 1) were removed from the dataset, <italic>K<sub>D,s</sub></italic> were averaged across biological replicates, and <italic>K<sub>D,s</sub></italic> with large SEM (&gt;0.5 log units) were excluded from subsequent analyses. This filtering retained 65,530, 63,840, and 64,619 genotypes for the MA90, G189E, and SI06 Tite-Seq experiments, respectively (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></sec><sec id="s4-5-3"><title>Expression data</title><p>Sequencing reads corresponding to the expression sort were handled identically to those from the HA binding sort, and the mean log-fluorescence was inferred as detailed above. Day-to-day variation in fluorophore labeling and detection were accounted for by normalizing mean log-fluorescence values by the average mean log-fluorescence of the corresponding biological replicate (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></sec><sec id="s4-5-4"><title>Force-directed layouts</title><p>To reduce the dimensionality of the sequence-affinity landscape, we implemented a force-directed layout, as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). In these graphs, each variant sequence is represented by a node, and variants related by a single mutation are connected by an edge. Edge weights between nodes <italic>s</italic> and <italic>t</italic> are weighted by the change in binding affinity resulting from the corresponding mutation:<disp-formula id="equ6"><mml:math id="m6"><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn><mml:mo>+</mml:mo><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>To construct the force-directed layout, we use <italic>K<sub>D,s</sub></italic> to MA90 to compute the weights. If a mutation from sequence s to t does not impact <italic>K<sub>D,s</sub></italic>, those nodes will be close together, and vice versa. The layout coordinates for each variant were obtained using the Python package iGraph function layout_drl, and each node is associated with the corresponding <italic>K<sub>D,s</sub></italic> to SI06 and G189E, as well as the mean expression. An interactive form of this graph is available as an online data browser at <ext-link ext-link-type="uri" xlink:href="https://ch65-ma90-browser.netlify.app/">https://ch65-ma90-browser.netlify.app/</ext-link>.</p></sec></sec><sec id="s4-6"><title>Epistasis analysis</title><sec id="s4-6-1"><title>Linear interaction models</title><p>We infer epistatic coefficients as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). Briefly, we implement linear models to infer specific mutational effects and interactions that sum to the observed log-transformed binding affinities, -log(<italic>K<sub>D,s</sub></italic>), which are proportional to free energy changes and hence expected to be additive (<xref ref-type="bibr" rid="bib92">Wells, 1990</xref>; <xref ref-type="bibr" rid="bib65">Olson et al., 2014</xref>). This additive model is given by:<disp-formula id="equ7"><mml:math id="m7"><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:mi>ε</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <italic>L</italic> is the number of mutations in CH65 (i.e., 16), <italic>β<sub>0</sub></italic> is an intercept, <italic>β <sub>i</sub></italic> is the effect of mutation at site, <italic>i</italic>, <italic>x<sub>i,s</sub></italic> is the genotype of variant <italic>s</italic> at site <italic>i</italic>, and <italic>ε</italic> represents independently and identically distributed errors. Our general epistatic model is thus given by<disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>j</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mo>…</mml:mo><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>ε</mml:mi></mml:mrow></mml:math></disp-formula></p><p>where <italic>β<sub>ij</sub></italic> are second-order interaction coefficients between sites <italic>i</italic> and <italic>j</italic>, <italic>β<sub>ijk</sub></italic> are third-order interaction coefficients between sites <italic>i</italic>, <italic>j</italic>, and <italic>k</italic>, and so on, up to a specified maximum order of interaction.</p><p>We infer these coefficients in both the biochemical and statistical bases (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Poelwijk et al., 2019</xref>), which are equivalent frameworks related by a linear transformation. For ease of interpretation, we report coefficients inferred using the biochemical model in the main text and figures as these coefficients can be interpreted as mutational effects and interactions relative to the UCA860 sequence. We report coefficients inferred using the statistical model in the figure supplements, and these mutational effects and coefficients can be interpreted as relative to the average of the dataset <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>.</p><p>For both biochemical and statistical models, we take a conservative approach to estimating higher-order epistasis. To this end, we truncate the model above some maximal order n and fit the resulting model using a Ridge L2 regularization, beginning with n = 1 and proceeding with higher <italic>n</italic> until the optimal performing model has been identified. We evaluate performance using a cross-validation approach. For each of eight random folds, we use 90% of the data to train the model and evaluate the model using the prediction performance (<italic>R<sup>2</sup></italic>) on the remaining 10%. We then average performance across the eight folds, select the order that maximizes the prediction performance, and retrain the entire dataset on a model truncated at this optimal order, this time by ordinary least-squares regression. This inference yields models with <italic>p</italic> coefficients, and we find that for each antigen <italic>P</italic> &lt; <italic>N</italic> by an order of magnitude, where <italic>N</italic> is the number of data points, giving us confidence that we are not overfitting the data.</p><p>Practically, we perform this inference using the Python package stats models using ordinary least-squares regression. This yields the coefficient values and associated standard errors and 95% confidence intervals (<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>); coefficients with 95% confidence intervals that do not cross zero are considered significant and are plotted in <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref>–<xref ref-type="fig" rid="fig3s3">3</xref>. For the SI06 data, we exclude N52H from the epistasis inference and perform the analysis on the remaining 15 mutations as &gt;90% of sequences with any detectable binding affinity include mutation N52H and thus we do not have power to infer the effect of this mutation. In the statistical epistasis inference, the coefficients at different orders are statistically independent and so we partition the variance explained by the model for each interaction order (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>).</p></sec><sec id="s4-6-2"><title>Structural analysis of epistasis</title><p>To examine the structural context of the first-order and pairwise coefficients from the biochemical epistasis model, we performed two analyses using the co-crystal structure of CH65 with full-length Influenza A/Solomon Islands/3/2006 HA (PDB 5UGY; <xref ref-type="bibr" rid="bib93">Whittle et al., 2011</xref>). First, we used ChimeraX (<xref ref-type="bibr" rid="bib69">Pettersen et al., 2021</xref>) to compute the buried surface area between each mutation in CH65 and HA using the <italic>measure buriedarea</italic> function and the default <italic>probeRadius</italic> of 1.4 Angstroms. This area is plotted as the ‘HA contact surface area’ in <xref ref-type="fig" rid="fig3">Figure 3</xref>. We perform the same computation between each mutation in CH65 and the HCDR3, and plot this as the ‘CDR3 contact surface area’ in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Second, we used PyMol (The PyMOL Molecular Graphics System, version 2.0 Schrödinger, LLC) to compute the distance between alpha-carbons, and plot this as a function of the pairwise interaction terms in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></sec></sec><sec id="s4-7"><title>Pathway analysis</title><sec id="s4-7-1"><title>Selection models</title><p>To assess the likelihood of mutational pathways from UCA860 to CH65, we assume a moderate selection model in the weak-mutation strong-selection regime as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>). Briefly, in this model, mutations fix independently of each other, and mutations are favored if they improve affinity, though both neutral and deleterious mutations are allowed. We use this model to compute the fixation probability of a mutation from sequence <italic>s</italic> to <italic>t</italic> (<xref ref-type="bibr" rid="bib49">Kuraoka et al., 2016</xref><xref ref-type="bibr" rid="bib45">Kimura, 1962</xref>). This fixation probability is then used to compute the transition probability of the corresponding mutational step:<disp-formula id="equ9"><mml:math id="m9"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>σ</mml:mi><mml:mo>,</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>σ</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>N</mml:mi><mml:mi>σ</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>We define the selection coefficient <italic>σ</italic> to be proportional to the difference in -log<italic>K<sub>D</sub></italic> for a particular antigen between sequences <italic>s</italic> and <italic>t</italic>:<disp-formula id="equ10"><mml:math id="m10"><mml:mi>σ</mml:mi><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mi>γ</mml:mi><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:mo>(</mml:mo><mml:mo>-</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <italic>N</italic> is the effective population size and γ corresponds to the strength of selection. For the moderate selection model applied here, we use N = 1000 and <italic>γ</italic> = 1. Additionally, to compute the total number of mutational paths that improve in affinity at each step, we use <italic>N</italic> → infinity and γ → infinity such that <italic>p<sub>step</sub></italic> = 1 if the mutation improves affinity and <italic>p<sub>step</sub></italic> = 0 otherwise. These fixation probabilities are then used to compute the transition probability for all sequences <italic>s,t</italic> over all antigens <italic>ag</italic>:<disp-formula id="equ11"><mml:math id="m11"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" rowspacing=".2em" columnspacing="1em" displaystyle="false"><mml:mtr><mml:mtd><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>N</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext></mml:mtd><mml:mtd><mml:mtext>o</mml:mtext><mml:mtext>t</mml:mtext><mml:mtext>h</mml:mtext><mml:mtext>e</mml:mtext><mml:mtext>r</mml:mtext><mml:mtext>w</mml:mtext><mml:mtext>i</mml:mtext><mml:mtext>s</mml:mtext><mml:mtext>e</mml:mtext></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-7-2"><title>Antigen selection scenario likelihood and mutation probabilities</title><p>The transition probabilities described above were used to compute the total probability for a set of possible antigen selection scenarios, and for select antigen selection scenarios, the probability of each mutation occurring at a specific order (<xref ref-type="fig" rid="fig5">Figure 5</xref>). This was performed as previously described (<xref ref-type="bibr" rid="bib71">Phillips et al., 2021</xref>), where the probabilities <inline-formula><mml:math id="inf4"><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> are stored as sparse transition matrices <inline-formula><mml:math id="inf5"><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi> </mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> of dimension 2<sup>N</sup> × 2<sup>N</sup> for each antigen, where entries are nonzero when sequence <italic>t</italic> has one more mutation than sequence <italic>s</italic>. To evaluate the total probability for a given antigen selection scenario, we compute the matrix product for all mutational steps <italic>i</italic> under a specific sequence of antigen selection contexts ag<sub>1</sub>, …, ag<sub>L</sub>:<disp-formula id="equ12"><mml:math id="m12"><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mtext>tot</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mtext>paths</mml:mtext></mml:mrow></mml:munder><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:munder><mml:mo>∏</mml:mo><mml:mrow><mml:mtext>steps</mml:mtext></mml:mrow></mml:munder><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where [.]<italic><sub>s,s’</sub></italic> represents the matrix element in the row corresponding to genotype <italic>s</italic> and the column corresponding to genotype <italic>s’</italic>. Notably, transition probabilities are not normalized at each step. Thus, many pathways will not reach the somatic CH65 sequence and the likelihood assesses the probability of reaching the CH65 somatic sequence.</p><p>Here, we consider three classes of antigen selection scenarios. The simplest is a single-antigen selection scenario, in which all steps <italic>i</italic> use the same antigen. Second, we consider selection scenarios where steps can use different antigens in a non-repetitive manner. Finally, we consider a scenario that approximates exposure to a mixture of antigens (<xref ref-type="bibr" rid="bib89">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib90">Wang, 2017</xref>; <xref ref-type="bibr" rid="bib49">Kuraoka et al., 2016</xref>), in which an antigen is drawn at random for each mutational step <italic>i</italic>. We then calculate <italic>P<sub>tot</sub></italic> for 1000 randomly drawn scenarios, report the average log probability, and illustrate mutational paths and orders for a scenario near the median probability from the 1000 draws. For all antigen selection scenarios, the error of <italic>P<sub>tot</sub></italic> is estimated by resampling the binding affinity from a normal distribution corresponding to its value and standard deviation. We perform this bootstrapping over 10 iterations and report <italic>P<sub>tot</sub></italic> as the average.</p><p>To identify the most likely paths under a given selection scenario (as plotted in <xref ref-type="fig" rid="fig5">Figure 5B</xref>), we construct a directed graph, where each sequence <italic>s</italic> is a node, and edges connect nodes <italic>s</italic> and <italic>t</italic> that are separated by one mutation. The edge weights are calculated from the transition probability, <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>→</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>ϵ</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></inline-formula> In this framework, we can use the <italic>shortest_simple_paths</italic> function in Python package <italic>networkx</italic> (<xref ref-type="bibr" rid="bib39">Hagberg et al., 2022</xref>) to compute the most likely paths.</p><p>To calculate the probability that a mutation at site m happened at a specific step j, we normalize the transition matrix (i.e., all paths must reach the somatic CH65 sequence) for a given antigen selection context:<disp-formula id="equ13"><mml:math id="m13"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>×</mml:mo><mml:mi> </mml:mi><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></disp-formula></p><p>For <inline-formula><mml:math id="inf7"><mml:msubsup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msubsup><mml:mo>≠</mml:mo></mml:math></inline-formula> 0 and 0 otherwise. The total relative probability for that site mutating at a specific step under an antigen exposure scenario is given by<disp-formula id="equ14"><mml:math id="m14"><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced><mml:mi> </mml:mi><mml:mo>∙</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mi> </mml:mi><mml:mo>∙</mml:mo><mml:mi> </mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></disp-formula></p><p>Finally, to determine the total probability of each variant (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), which is given by the sum of the probabilities of all paths passing through that variant in a specific antigen selection scenario:<disp-formula id="equ15"><mml:math id="m15"><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>∙</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>where <italic>j</italic> is the number of somatic mutations in variant <italic>s</italic>, the first term is the probability of reaching sequence s at mutational step <italic>j</italic>, and the second term is the probability of reaching the CH65 sequence after passing through sequence <italic>s</italic>. We perform an additional normalization, <inline-formula><mml:math id="inf8"><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mo>×</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , so that variants with different numbers of mutations can be compared. <inline-formula><mml:math id="inf9"><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is thus the probability of a specific variant in the selective model compared to a neutral model (e.g., sequences with log(<inline-formula><mml:math id="inf10"><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">Ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) &gt; 0 are favored).</p></sec></sec><sec id="s4-8"><title>Isogenic <italic>K</italic><sub>D</sub> measurements</title><p>To validate <italic>K<sub>D</sub></italic> measurements made using Tite-Seq, we generated isogenic yeast strains encoding select variants in the CH65 scFv library and measured their affinity to HA using analytical flow cytometry. These variants were constructed by the same Golden Gate strategy used above for the library, but by pooling one version of each fragment rather than all versions of each fragment. The assembled plasmid was sequence-verified via Sanger, transformed into the EBY100 yeast strain, plated on SDCAA-agar, and incubated at 30°C for 48 hr. Single colonies were then restruck onto SDCAA-agar and grown for an additional 48 hr at 30°C for further selection. These restruck colonies were verified to contain the scFv plasmid by colony PCR. Verified colonies were then grown in 5 mL SDCAA with rotation at 30°C for 24 hr; strains were stored by freezing saturated cultures with 5% glycerol at –80°C.</p><p>To measure <italic>K<sub>D</sub></italic>, yeast strains were thawed and scFv were induced, incubated with HA antigen, and labeled with fluorophores as described above for the Tite-Seq assay, except yeast cell and antigen volumes were scaled down by a factor of 10. Yeast cell FITC and R-PE fluorescence intensity were then assayed on a BD LSR Fortessa equipped with four lasers (440, 488, 561, and 633 nm), sampling at least 10,000 events per concentration. The equilibrium dissociation constant, <italic>K<sub>D</sub></italic>, were then inferred for each variant <italic>s</italic> by fitting the logarithm of a Hill function to the mean log R-PE fluorescence for the scFv-expression (FITC-positive) single yeast cells:<disp-formula id="equ16"><mml:math id="m16"><mml:mtext>mean log fluorescence = </mml:mtext><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <italic>c</italic> is the molarity of antigen, <italic>A<sub>s</sub></italic> is the increase in fluorescence due to saturation with antigen, and <italic>B<sub>s</sub></italic> is the background fluorescence. All isogenic <italic>K<sub>D</sub></italic> measurements were made in 2–3 biological replicates (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p></sec><sec id="s4-9"><title>Fab structural characterization</title><sec id="s4-9-1"><title>Fab production and purification</title><p>Antigen binding fragments were cloned and produced in Expi293F cells as above, except the variable heavy chain was cloned into a pVRC expression vector containing the CH1 domain followed by a HRV 3C cleavate site and a 6X His tag. Fabs were purified by cobalt chromatography (Takara) and further purified over an S200 column on an AKTA pure (Cytiva). To the purified Fabs, 1.2 μL HRV 3C protease (Thermo Scientific, #88947) per 200 μg of Fab was added and incubated overnight at 4°C on a roller. The next day, the cleaved Fab was passed over cobalt resin and purified again over an S200 column in 10 mM Tris HCl, 150 mM NaCl, pH 7.5. The resulting Fabs were concentrated to ~15 mg/mL prior to crystallization.</p></sec><sec id="s4-9-2"><title>Fab crystallization</title><p>Fabs were crystallized by the hanging drop method. Crystals of unbound UCA Fab with the Y35N (LC) mutation and unbound I-2 Fab with H35N (HC) and Y35N (LC) mutations were grown over solutions of 0.1 M succinic acid (pH 7), 0.1 M bicine (pH 8.5), and 30% polyethylene glycol monomethyl ether 550 or 0.8 M lithium sulfate monohydrate, 0.1 M sodium acetate trihydrate (pH 4), and 4% polyethylene glycol 200 (Hampton Research, #HR2-084), respectively, in a 96-well plate (Greiner, #655101) with ViewDrop II plate seals (sptlabtech, #4150-05600). Crystals were apparent after ~5–7 days. Then, 1 μL of 12% (+/-)-2-methyl-2,4-pentanediol (MPD) in the corresponding solution was added for cryoprotection. The crystals were then harvested and flash-cooled in liquid nitrogen.</p></sec><sec id="s4-9-3"><title>Fab structure determination</title><p>X-ray diffraction data was collected at the Advanced Photon Source using beam line 24-ID-E. Diffraction data was processed using XDSGUI (<ext-link ext-link-type="uri" xlink:href="https://strucbio.biologie.uni-konstanz.de/xdswiki/index.php/XDSGUI">https://strucbio.biologie.uni-konstanz.de/xdswiki/index.php/XDSGUI</ext-link>). Both Fabs reported here were solved by molecular replacement using PHASER in the PHENIX-MR GUI (<xref ref-type="bibr" rid="bib2">Adams et al., 2002</xref>; <xref ref-type="bibr" rid="bib57">McCoy et al., 2007</xref>) by searching with the UCA Fab (PDB: 4HK0) (<xref ref-type="bibr" rid="bib77">Schmidt et al., 2013</xref>) with the HCDR3 deleted and separated into the VH, VL, CH, and CL domains. Refinement was performed in PHENIX (<xref ref-type="bibr" rid="bib2">Adams et al., 2002</xref>) by refining the coordinates and B factors before model building (i.e., the HCDR3) in COOT (<xref ref-type="bibr" rid="bib28">Emsley et al., 2010</xref>). Additional placement of waters and Translation Libration Screw (TLS) refinement followed. The UCA with Y35N Fab showed density for the HCDR3, which was built, but this loop exhibited large B factors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The I-2 with H35N and Y35N Fab showed no clear density for the HCDR3 or the LCDR2 so these were removed from the structure. The resulting structures were validated using MolProbity (<xref ref-type="bibr" rid="bib17">Chen et al., 2010</xref>) prior to deposition at the Protein Data Bank (8EK6 and 8EKH).</p></sec></sec><sec id="s4-10"><title>Antibody-antigen binding kinetics measurements</title><p>Kinetics measurements were acquired on an Octet RED96e (Sartorius). To mimic the interaction between yeast-displayed scFv and trimeric HA, IgG was loaded onto Anti-Human Fc Capture (AHC) biosensors (Sartorius, #18-5060). To reduce the avidity effect, IgGs were loaded to a density of ~0.1 nm using a solution of 10 nM of IgG. All binding measurements were obtained in 'kinetics' buffer: PBS supplemented with 0.1% BSA and 0.01% Tween20. Binding measurements were acquired as follows with shaking at 1000 rpm – baseline: 60 s; loading: 30 s with threshold at 0.1 nm; baseline: 60 s; association: 360 s; dissociation: 600 s. Tips were regenerated a maximum of four times by alternating between 10 mM glycine (pH 1.7) and kinetics buffer three times with 10 s in each buffer. Kinetics measurements were obtained at four temperatures for each antibody: 20, 25, 30, and 35°C. Kinetics measurements for the UCA, I-2, and CH65 were also acquired at 40°C. Prior to each measurement, the plate was allowed to equilibrate to the set temperature for 20 min. Each full-length, trimeric HA (MA90, MA90-G189E, and SI06) was assayed at six concentrations: 500, 250, 125, 62.5, 31.25, and 15.625 nM. For each antibody against each HA, antibody assayed with buffer only was used as a reference for subtraction. Additionally, each run contained an irrelevant IgG (CR3022) at the highest HA concentration (500 nM) to detect any nonspecific interaction, which was at background level. To account for the multivalency of the analyte (trimeric HA), the bivalent analyte model was used for global curve fitting in the Sartorius Data Analysis HT software version 12.0.2.59.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>has recently consulted for Leyden Labs</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>recently consulted for Leyden Labs</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Plasmid map of pCHA with UCA860 scFv sequence.</title></caption><media xlink:href="elife-83628-supp1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Plasmid map of pCHA with CH65 scFv sequence.</title></caption><media xlink:href="elife-83628-supp2-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Primers for constructing CH65 combinatorial mutation library.</title></caption><media xlink:href="elife-83628-supp3-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Primers for sequencing library preparation.</title></caption><media xlink:href="elife-83628-supp4-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>MA90 full-length soluble ectodomain HA expression construct.</title></caption><media xlink:href="elife-83628-supp5-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>MA90-G189E full-length soluble ectodomain expression construct.</title></caption><media xlink:href="elife-83628-supp6-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>SI06 full-length soluble ectodomain HA expression construct.</title></caption><media xlink:href="elife-83628-supp7-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83628-mdarchecklist1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data and code used for this study are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/amphilli/CH65-comblib">https://github.com/amphilli/CH65-comblib</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:4f7d51e6648e51967e15739e7d0229d81d22e175;origin=https://github.com/amphilli/CH65-comblib;visit=swh:1:snp:23ca052a3116970194f9ab1124e3b0828a48b22d;anchor=swh:1:rev:cea336dfd05fa31d675f79038428bf7f0d177e78">swh:1:rev:cea336dfd05fa31d675f79038428bf7f0d177e78</ext-link>). Antibody affinity and expression data are also available in an interactive data browser at <ext-link ext-link-type="uri" xlink:href="https://ch65-ma90-browser.netlify.app/">https://ch65-ma90-browser.netlify.app/</ext-link>. FASTQ files from high-throughput sequencing are deposited in the NCBI BioProject database under PRJNA886089. X-ray crystal structures of the Fabs reported here are available at the Protein Data Bank (8EK6 and 8EKH).</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Maurer</surname><given-names>DP</given-names></name><name><surname>Brooks</surname><given-names>C</given-names></name><name><surname>Dupic</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Desai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Binding affinity landscape of CH65 to divergent influenza H1 strains</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA886089/">PRJNA886089</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Maurer</surname><given-names>DP</given-names></name><name><surname>Brooks</surname><given-names>C</given-names></name><name><surname>Dupic</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Desai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>CH65 Tite-Seq KD Measurements</data-title><source>CH65 online data browser</source><pub-id pub-id-type="accession" xlink:href="https://ch65-ma90-browser.netlify.app">ch65-ma90</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Zach Niziolek for assistance with flow cytometry and members of the Desai lab for helpful discussions. We thank Jesse Bloom for providing the plasmids required to generate recombinant influenza viruses and Nicholas Heaton for sharing influenza virus-related protocols. AMP acknowledges support from the Howard Hughes Medical Institute Hanna H Gray Postdoctoral Fellowship, TD acknowledges support from the Human Frontier Science Program Postdoctoral Fellowship, AGS acknowledges support for NIH grants R01AI146779 and P01AI89618-A1, MMD acknowledges support from the NSF-Simons Center for Mathematical and Statistical Analysis of Biology at Harvard University, supported by NSF grant no. DMS-1764269, and the Harvard FAS Quantitative Biology Initiative, grant DEB-1655960 from the NSF and grant GM104239 from the NIH. Computational work was performed on the FASRC Cannon cluster supported by the FAS Division of Science Research Computing Group at Harvard University. We thank the beamline staff at NE-CAT for help with data collection; this work used NE-CAT beamlines (GM124165), a Pilatus detector (RR029205), an Eiger detector (OD021527) at the APS (DE-AC02-06CH11357).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RK</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Menis</surname><given-names>S</given-names></name><name><surname>Skog</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>M</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Kulp</surname><given-names>DW</given-names></name><name><surname>Bhullar</surname><given-names>D</given-names></name><name><surname>Kalyuzhniy</surname><given-names>O</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens</article-title><source>Immunity</source><volume>48</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.023</pub-id><pub-id pub-id-type="pmid">29287996</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Ioerger</surname><given-names>TR</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Sacchettini</surname><given-names>JC</given-names></name><name><surname>Sauter</surname><given-names>NK</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>PHENIX: building new software for automated crystallographic structure determination</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>58</volume><fpage>1948</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1107/s0907444902016657</pub-id><pub-id pub-id-type="pmid">12393927</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>RM</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Kinney</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves</article-title><source>eLife</source><volume>5</volume><elocation-id>e23156</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.23156</pub-id><pub-id pub-id-type="pmid">28035901</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>RM</given-names></name><name><surname>Kinney</surname><given-names>JB</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epistasis in a fitness landscape defined by antibody-antigen binding free energy</article-title><source>Cell Systems</source><volume>8</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.12.004</pub-id><pub-id pub-id-type="pmid">30611676</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amon</surname><given-names>R</given-names></name><name><surname>Rosenfeld</surname><given-names>R</given-names></name><name><surname>Perlmutter</surname><given-names>S</given-names></name><name><surname>Grant</surname><given-names>OC</given-names></name><name><surname>Yehuda</surname><given-names>S</given-names></name><name><surname>Borenstein-Katz</surname><given-names>A</given-names></name><name><surname>Alcalay</surname><given-names>R</given-names></name><name><surname>Marshanski</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Woods</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Padler-Karavani</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Directed evolution of therapeutic antibodies targeting glycosylation in cancer</article-title><source>Cancers</source><volume>12</volume><elocation-id>2824</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12102824</pub-id><pub-id pub-id-type="pmid">33007970</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Popova</surname><given-names>LI</given-names></name><name><surname>Ho</surname><given-names>IY</given-names></name><name><surname>Pauli</surname><given-names>NT</given-names></name><name><surname>Henry Dunand</surname><given-names>CJ</given-names></name><name><surname>Taylor</surname><given-names>WM</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Salgado-Ferrer</surname><given-names>M</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immune history profoundly affects broadly protective B cell responses to influenza</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>316ra192</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aad0522</pub-id><pub-id pub-id-type="pmid">26631631</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeletti</surname><given-names>D</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Is it possible to develop a “ universal ” influenza virus vaccine? outflanking antibody immunodominance on the road to universal influenza vaccination</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>10</volume><elocation-id>a028852</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028852</pub-id><pub-id pub-id-type="pmid">28663210</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajic</surname><given-names>G</given-names></name><name><surname>van der Poel</surname><given-names>CE</given-names></name><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Carroll</surname><given-names>MC</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>3492</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-40175-8</pub-id><pub-id pub-id-type="pmid">30837606</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bank</surname><given-names>C</given-names></name><name><surname>Hietpas</surname><given-names>RT</given-names></name><name><surname>Jensen</surname><given-names>JD</given-names></name><name><surname>Bolon</surname><given-names>DNA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A systematic survey of an intragenic epistatic landscape</article-title><source>Molecular Biology and Evolution</source><volume>32</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1093/molbev/msu301</pub-id><pub-id pub-id-type="pmid">25371431</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedford</surname><given-names>T</given-names></name><name><surname>Suchard</surname><given-names>MA</given-names></name><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Dudas</surname><given-names>G</given-names></name><name><surname>Gregory</surname><given-names>V</given-names></name><name><surname>Hay</surname><given-names>AJ</given-names></name><name><surname>McCauley</surname><given-names>JW</given-names></name><name><surname>Russell</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Integrating influenza antigenic dynamics with molecular evolution</article-title><source>eLife</source><volume>3</volume><elocation-id>e01914</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.01914</pub-id><pub-id pub-id-type="pmid">24497547</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boder</surname><given-names>ET</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Yeast surface display for screening combinatorial polypeptide libraries</article-title><source>Nature Biotechnology</source><volume>15</volume><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/nbt0697-553</pub-id><pub-id pub-id-type="pmid">9181578</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bowers</surname><given-names>PM</given-names></name><name><surname>Bowers</surname><given-names>WJ</given-names></name><name><surname>Damoiseaux</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><source>Antibody Engineering: Methods and Protocols</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4939-8648-4</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braden</surname><given-names>BC</given-names></name><name><surname>Goldman</surname><given-names>ER</given-names></name><name><surname>Mariuzza</surname><given-names>RA</given-names></name><name><surname>Poljak</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3</article-title><source>Immunological Reviews</source><volume>163</volume><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065x.1998.tb01187.x</pub-id><pub-id pub-id-type="pmid">9700501</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burks</surname><given-names>EA</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Iverson</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>In vitro scanning saturation mutagenesis of an antibody binding pocket</article-title><source>PNAS</source><volume>94</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.2.412</pub-id><pub-id pub-id-type="pmid">9012796</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>G</given-names></name><name><surname>Lau</surname><given-names>WL</given-names></name><name><surname>Hackel</surname><given-names>BJ</given-names></name><name><surname>Sazinsky</surname><given-names>SL</given-names></name><name><surname>Lippow</surname><given-names>SM</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Isolating and engineering human antibodies using yeast surface display</article-title><source>Nature Protocols</source><volume>1</volume><fpage>755</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.94</pub-id><pub-id pub-id-type="pmid">17406305</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wiesmann</surname><given-names>C</given-names></name><name><surname>Fuh</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Christinger</surname><given-names>HW</given-names></name><name><surname>McKay</surname><given-names>P</given-names></name><name><surname>de Vos</surname><given-names>AM</given-names></name><name><surname>Lowman</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen</article-title><source>Journal of Molecular Biology</source><volume>293</volume><fpage>865</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.3192</pub-id><pub-id pub-id-type="pmid">10543973</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Arendall</surname><given-names>WB</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Keedy</surname><given-names>DA</given-names></name><name><surname>Immormino</surname><given-names>RM</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Murray</surname><given-names>LW</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id><pub-id pub-id-type="pmid">20057044</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Voss</surname><given-names>J</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name><name><surname>Codoni</surname><given-names>G</given-names></name><name><surname>Macagno</surname><given-names>A</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Vachieri</surname><given-names>SG</given-names></name><name><surname>Pinna</surname><given-names>D</given-names></name><name><surname>Minola</surname><given-names>A</given-names></name><name><surname>Vanzetta</surname><given-names>F</given-names></name><name><surname>Silacci</surname><given-names>C</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>BM</given-names></name><name><surname>Agatic</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Giacchetto-Sasselli</surname><given-names>I</given-names></name><name><surname>Calder</surname><given-names>L</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Haire</surname><given-names>LF</given-names></name><name><surname>Temperton</surname><given-names>N</given-names></name><name><surname>Langedijk</surname><given-names>JPM</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins</article-title><source>Science</source><volume>333</volume><fpage>850</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1126/science.1205669</pub-id><pub-id pub-id-type="pmid">21798894</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Broadly neutralizing antiviral antibodies</article-title><source>Annual Review of Immunology</source><volume>31</volume><fpage>705</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095916</pub-id><pub-id pub-id-type="pmid">23330954</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Kallewaard</surname><given-names>NL</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tackling influenza with broadly neutralizing antibodies</article-title><source>Current Opinion in Virology</source><volume>24</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.002</pub-id><pub-id pub-id-type="pmid">28527859</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Visser</surname><given-names>JAGM</given-names></name><name><surname>Elena</surname><given-names>SF</given-names></name><name><surname>Fragata</surname><given-names>I</given-names></name><name><surname>Matuszewski</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The utility of fitness landscapes and big data for predicting evolution</article-title><source>Heredity</source><volume>121</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/s41437-018-0128-4</pub-id><pub-id pub-id-type="pmid">30127530</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiLillo</surname><given-names>DJ</given-names></name><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo</article-title><source>Nature Medicine</source><volume>20</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/nm.3443</pub-id><pub-id pub-id-type="pmid">24412922</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyfus</surname><given-names>C</given-names></name><name><surname>Laursen</surname><given-names>NS</given-names></name><name><surname>Kwaks</surname><given-names>T</given-names></name><name><surname>Zuijdgeest</surname><given-names>D</given-names></name><name><surname>Khayat</surname><given-names>R</given-names></name><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Metlagel</surname><given-names>Z</given-names></name><name><surname>Bujny</surname><given-names>MV</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>van der Vlugt</surname><given-names>R</given-names></name><name><surname>Lamrani</surname><given-names>M</given-names></name><name><surname>Korse</surname><given-names>HJWM</given-names></name><name><surname>Geelen</surname><given-names>E</given-names></name><name><surname>Sahin</surname><given-names>Ö</given-names></name><name><surname>Sieuwerts</surname><given-names>M</given-names></name><name><surname>Brakenhoff</surname><given-names>JPJ</given-names></name><name><surname>Vogels</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>OTW</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Friesen</surname><given-names>RHE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Highly conserved protective epitopes on influenza B viruses</article-title><source>Science</source><volume>337</volume><fpage>1343</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1126/science.1222908</pub-id><pub-id pub-id-type="pmid">22878502</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugan</surname><given-names>HL</given-names></name><name><surname>Guthmiller</surname><given-names>JJ</given-names></name><name><surname>Arevalo</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Neu</surname><given-names>KE</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Lan</surname><given-names>LYL</given-names></name><name><surname>Tepora</surname><given-names>ME</given-names></name><name><surname>Stovicek</surname><given-names>O</given-names></name><name><surname>Bitar</surname><given-names>D</given-names></name><name><surname>Palm</surname><given-names>AKE</given-names></name><name><surname>Stamper</surname><given-names>CT</given-names></name><name><surname>Changrob</surname><given-names>S</given-names></name><name><surname>Utset</surname><given-names>HA</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Cobey</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eabd3601</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abd3601</pub-id><pub-id pub-id-type="pmid">33298562</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Bhabha</surname><given-names>G</given-names></name><name><surname>Elsliger</surname><given-names>M-A</given-names></name><name><surname>Friesen</surname><given-names>RHE</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>Throsby</surname><given-names>M</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Antibody recognition of a highly conserved influenza virus epitope</article-title><source>Science</source><volume>324</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1126/science.1171491</pub-id><pub-id pub-id-type="pmid">19251591</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>DC</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Broadly neutralizing antibodies against influenza virus and prospects for universal therapies</article-title><source>Current Opinion in Virology</source><volume>2</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2012.02.005</pub-id><pub-id pub-id-type="pmid">22482710</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellebedy</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Immunizing the immune: can we overcome influenza’s most formidable challenge?</article-title><source>Vaccines</source><volume>6</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines6040068</pub-id><pub-id pub-id-type="pmid">30248996</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engler</surname><given-names>C</given-names></name><name><surname>Kandzia</surname><given-names>R</given-names></name><name><surname>Marillonnet</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A one pot, one step, precision cloning method with high throughput capability</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e3647</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003647</pub-id><pub-id pub-id-type="pmid">18985154</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fera</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains</article-title><source>PNAS</source><volume>111</volume><fpage>10275</fpage><lpage>10280</lpage><pub-id pub-id-type="doi">10.1073/pnas.1409954111</pub-id><pub-id pub-id-type="pmid">24982157</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsyth</surname><given-names>CM</given-names></name><name><surname>Juan</surname><given-names>V</given-names></name><name><surname>Akamatsu</surname><given-names>Y</given-names></name><name><surname>DuBridge</surname><given-names>RB</given-names></name><name><surname>Doan</surname><given-names>M</given-names></name><name><surname>Ivanov</surname><given-names>AV</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Polakoff</surname><given-names>D</given-names></name><name><surname>Razo</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><name><surname>Powers</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing</article-title><source>MAbs</source><volume>5</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.4161/mabs.24979</pub-id><pub-id pub-id-type="pmid">23765106</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Friedl</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><source>Mastering Regular Expressions</source><edition>3rd edition</edition><publisher-name>O’Reilly Media</publisher-name></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>DG</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Chuang</surname><given-names>RY</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><name><surname>Hutchison</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>HO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title><source>Nature Methods</source><volume>6</volume><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1318</pub-id><pub-id pub-id-type="pmid">19363495</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gietz</surname><given-names>RD</given-names></name><name><surname>Schiestl</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High-Efficiency yeast transformation using the liac/SS carrier DNA/PEG method</article-title><source>Nature Protocols</source><volume>2</volume><fpage>31</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.13</pub-id><pub-id pub-id-type="pmid">17401334</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>LI</given-names></name><name><surname>Suchard</surname><given-names>MA</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Stability-mediated epistasis constrains the evolution of an influenza protein</article-title><source>eLife</source><volume>2</volume><elocation-id>e00631</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00631</pub-id><pub-id pub-id-type="pmid">23682315</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthmiller</surname><given-names>JJ</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Harnessing immune history to combat influenza viruses</article-title><source>Current Opinion in Immunology</source><volume>53</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2018.05.010</pub-id><pub-id pub-id-type="pmid">29890370</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthmiller</surname><given-names>JJ</given-names></name><name><surname>Utset</surname><given-names>HA</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>B cell responses against influenza viruses: short-lived humoral immunity against a life-long threat</article-title><source>Viruses</source><volume>13</volume><elocation-id>965</elocation-id><pub-id pub-id-type="doi">10.3390/v13060965</pub-id><pub-id pub-id-type="pmid">34067435</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthmiller</surname><given-names>JJ</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Utset</surname><given-names>HA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lan</surname><given-names>LY-L</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Stamper</surname><given-names>CT</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>O’Dell</surname><given-names>G</given-names></name><name><surname>Fernández-Quintero</surname><given-names>ML</given-names></name><name><surname>Freyn</surname><given-names>AW</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Stovicek</surname><given-names>O</given-names></name><name><surname>Gentles</surname><given-names>L</given-names></name><name><surname>Richey</surname><given-names>ST</given-names></name><name><surname>de la Peña</surname><given-names>AT</given-names></name><name><surname>Rosado</surname><given-names>V</given-names></name><name><surname>Dugan</surname><given-names>HL</given-names></name><name><surname>Zheng</surname><given-names>N-Y</given-names></name><name><surname>Tepora</surname><given-names>ME</given-names></name><name><surname>Bitar</surname><given-names>DJ</given-names></name><name><surname>Changrob</surname><given-names>S</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Liedl</surname><given-names>KR</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Nachbagauer</surname><given-names>R</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Coughlan</surname><given-names>L</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Broadly neutralizing antibodies target a haemagglutinin anchor epitope</article-title><source>Nature</source><volume>602</volume><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04356-8</pub-id><pub-id pub-id-type="pmid">34942633</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>A</given-names></name><name><surname>Swart</surname><given-names>P</given-names></name><name><surname>Chult</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Sponsor org</data-title><source>USDOE</source></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Czajkowski</surname><given-names>L</given-names></name><name><surname>Rosas</surname><given-names>LA</given-names></name><name><surname>Cervantes-Medina</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gouzoulis</surname><given-names>M</given-names></name><name><surname>Lumbard</surname><given-names>K</given-names></name><name><surname>Hunsberger</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>S</given-names></name><name><surname>Athota</surname><given-names>R</given-names></name><name><surname>Baus</surname><given-names>HA</given-names></name><name><surname>Lwin</surname><given-names>A</given-names></name><name><surname>Sadoff</surname><given-names>J</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Memoli</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Safety and efficacy of CR6261 in an influenza A H1N1 healthy human challenge model</article-title><source>Clinical Infectious Diseases</source><volume>73</volume><fpage>e4260</fpage><lpage>e4268</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1725</pub-id><pub-id pub-id-type="pmid">33211860</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Hobom</surname><given-names>G</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A DNA transfection system for generation of influenza A virus from eight plasmids</article-title><source>PNAS</source><volume>97</volume><fpage>6108</fpage><lpage>6113</lpage><pub-id pub-id-type="doi">10.1073/pnas.100133697</pub-id><pub-id pub-id-type="pmid">10801978</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horns</surname><given-names>F</given-names></name><name><surname>Vollmers</surname><given-names>C</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Signatures of selection in the human antibody repertoire: selective sweeps, competing subclones, and neutral drift</article-title><source>PNAS</source><volume>116</volume><fpage>1261</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814213116</pub-id><pub-id pub-id-type="pmid">30622180</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horns</surname><given-names>F</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics</article-title><source>Cell Reports</source><volume>30</volume><fpage>905</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.12.063</pub-id><pub-id pub-id-type="pmid">31968262</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Weinstein</surname><given-names>JA</given-names></name><name><surname>Penland</surname><given-names>L</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>XS</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Greenberg</surname><given-names>HB</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>Fisher</surname><given-names>DS</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lineage structure of the human antibody repertoire in response to influenza vaccination</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>171ra119</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3004794</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1962">1962</year><article-title>On the probability of fixation of mutant genes in a population</article-title><source>Genetics</source><volume>47</volume><fpage>713</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1093/genetics/47.6.713</pub-id><pub-id pub-id-type="pmid">14456043</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Lammens</surname><given-names>A</given-names></name><name><surname>Schäfer</surname><given-names>W</given-names></name><name><surname>Georges</surname><given-names>G</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name><name><surname>Mössner</surname><given-names>E</given-names></name><name><surname>Hopfner</surname><given-names>KP</given-names></name><name><surname>Umaña</surname><given-names>P</given-names></name><name><surname>Niederfellner</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties</article-title><source>MAbs</source><volume>5</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.4161/mabs.22771</pub-id><pub-id pub-id-type="pmid">23211638</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>JC</given-names></name><name><surname>Tsibane</surname><given-names>T</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name><name><surname>Huffman</surname><given-names>CJ</given-names></name><name><surname>Basler</surname><given-names>CF</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin</article-title><source>Journal of Virology</source><volume>85</volume><fpage>10905</fpage><lpage>10908</lpage><pub-id pub-id-type="doi">10.1128/JVI.00700-11</pub-id><pub-id pub-id-type="pmid">21849447</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Miyauchi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Breadth of antibody responses during influenza virus infection and vaccination</article-title><source>Trends in Immunology</source><volume>41</volume><fpage>394</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.03.005</pub-id><pub-id pub-id-type="pmid">32265127</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuraoka</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Nojima</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Kitamura</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex antigens drive permissive clonal selection in germinal centers</article-title><source>Immunity</source><volume>44</volume><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.010</pub-id><pub-id pub-id-type="pmid">26948373</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Ohshima</surname><given-names>N</given-names></name><name><surname>Stanfield</surname><given-names>RL</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Iba</surname><given-names>Y</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Kurosawa</surname><given-names>Y</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3614</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4614</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Arnell</surname><given-names>AJ</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structure of the apo anti-influenza CH65 Fab</article-title><source>Acta Crystallographica. Section F, Structural Biology Communications</source><volume>71</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1107/S2053230X14027599</pub-id><pub-id pub-id-type="pmid">25664786</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Maziuk</surname><given-names>BF</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Wolozin</surname><given-names>B</given-names></name><name><surname>Cho</surname><given-names>YK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>12081</fpage><lpage>12094</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.003557</pub-id><pub-id pub-id-type="pmid">29899114</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Lynch</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name><name><surname>Fire</surname><given-names>AZ</given-names></name><name><surname>Roskin</surname><given-names>KM</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><collab>NISC Comparative Sequencing Program</collab><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Gnanakaran</surname><given-names>S</given-names></name><name><surname>Hraber</surname><given-names>P</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>S-M</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Lloyd</surname><given-names>KE</given-names></name><name><surname>Scearce</surname><given-names>RM</given-names></name><name><surname>Soderberg</surname><given-names>KA</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Kamanga</surname><given-names>G</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Tran</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Korber</surname><given-names>BTM</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Co-Evolution of a broadly neutralizing HIV-1 antibody and founder virus</article-title><source>Nature</source><volume>496</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature12053</pub-id><pub-id pub-id-type="pmid">23552890</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>McTamney</surname><given-names>PM</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>Whittle</surname><given-names>JRR</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Boyington</surname><given-names>JC</given-names></name><name><surname>Wei</surname><given-names>C-J</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural and genetic basis for development of broadly neutralizing influenza antibodies</article-title><source>Nature</source><volume>489</volume><fpage>566</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1038/nature11371</pub-id><pub-id pub-id-type="pmid">22932267</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mata-Fink</surname><given-names>J</given-names></name><name><surname>Kriegsman</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>HX</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Hanson</surname><given-names>MC</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast</article-title><source>Journal of Molecular Biology</source><volume>425</volume><fpage>444</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.11.010</pub-id><pub-id pub-id-type="pmid">23159556</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>KR</given-names></name><name><surname>Raymond</surname><given-names>DD</given-names></name><name><surname>Do</surname><given-names>KT</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Affinity maturation in a human humoral response to influenza hemagglutinin</article-title><source>PNAS</source><volume>116</volume><fpage>26745</fpage><lpage>26751</lpage><pub-id pub-id-type="doi">10.1073/pnas.1915620116</pub-id><pub-id pub-id-type="pmid">31843892</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Storoni</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phaser crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miton</surname><given-names>CM</given-names></name><name><surname>Tokuriki</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>How mutational epistasis impairs predictability in protein evolution and design</article-title><source>Protein Science</source><volume>25</volume><fpage>1260</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1002/pro.2876</pub-id><pub-id pub-id-type="pmid">26757214</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molari</surname><given-names>M</given-names></name><name><surname>Eyer</surname><given-names>K</given-names></name><name><surname>Baudry</surname><given-names>J</given-names></name><name><surname>Cocco</surname><given-names>S</given-names></name><name><surname>Monasson</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Quantitative modeling of the effect of antigen dosage on B-cell affinity distributions in maturating germinal centers</article-title><source>eLife</source><volume>9</volume><elocation-id>e55678</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.55678</pub-id><pub-id pub-id-type="pmid">32538783</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Walter</surname><given-names>EB</given-names></name><name><surname>Woods</surname><given-names>CW</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name><name><surname>McClain</surname><given-names>MT</given-names></name><name><surname>Denny</surname><given-names>TN</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Munshaw</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>DJ</given-names></name><name><surname>Whitesides</surname><given-names>JF</given-names></name><name><surname>Drinker</surname><given-names>MS</given-names></name><name><surname>Amos</surname><given-names>JD</given-names></name><name><surname>Gurley</surname><given-names>TC</given-names></name><name><surname>Eudailey</surname><given-names>JA</given-names></name><name><surname>Foulger</surname><given-names>A</given-names></name><name><surname>DeRosa</surname><given-names>KR</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Meyerhoff</surname><given-names>RR</given-names></name><name><surname>Yu</surname><given-names>J-S</given-names></name><name><surname>Kozink</surname><given-names>DM</given-names></name><name><surname>Barefoot</surname><given-names>BE</given-names></name><name><surname>Ramsburg</surname><given-names>EA</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Golding</surname><given-names>H</given-names></name><name><surname>Vandergrift</surname><given-names>NA</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e25797</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025797</pub-id><pub-id pub-id-type="pmid">22039424</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulana</surname><given-names>A</given-names></name><name><surname>Dupic</surname><given-names>T</given-names></name><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Nieves</surname><given-names>S</given-names></name><name><surname>Roffler</surname><given-names>AA</given-names></name><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Desai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Compensatory epistasis maintains ACE2 affinity in SARS-cov-2 omicron BA.1</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>7011</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-34506-z</pub-id><pub-id pub-id-type="pmid">36384919</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Schaefer-Babajew</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>C Lorenzi</surname><given-names>JC</given-names></name><name><surname>Flyak</surname><given-names>AI</given-names></name><name><surname>DeLaitsch</surname><given-names>AT</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Da Silva</surname><given-names>J</given-names></name><name><surname>Poston</surname><given-names>D</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Millard</surname><given-names>KG</given-names></name><name><surname>Ramos</surname><given-names>V</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Rutkowska</surname><given-names>M</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Affinity maturation of SARS-cov-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations</article-title><source>Immunity</source><volume>54</volume><fpage>1853</fpage><lpage>1868</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.07.008</pub-id><pub-id pub-id-type="pmid">34331873</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neher</surname><given-names>RA</given-names></name><name><surname>Bedford</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nextflu: real-time tracking of seasonal influenza virus evolution in humans</article-title><source>Bioinformatics</source><volume>31</volume><fpage>3546</fpage><lpage>3548</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv381</pub-id><pub-id pub-id-type="pmid">26115986</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen Ba</surname><given-names>AN</given-names></name><name><surname>Cvijović</surname><given-names>I</given-names></name><name><surname>Rojas Echenique</surname><given-names>JI</given-names></name><name><surname>Lawrence</surname><given-names>KR</given-names></name><name><surname>Rego-Costa</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>SF</given-names></name><name><surname>Desai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>High-Resolution lineage tracking reveals travelling wave of adaptation in laboratory yeast</article-title><source>Nature</source><volume>575</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1749-3</pub-id><pub-id pub-id-type="pmid">31723263</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>CA</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A comprehensive biophysical description of pairwise epistasis throughout an entire protein domain</article-title><source>Current Biology</source><volume>24</volume><fpage>2643</fpage><lpage>2651</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.09.072</pub-id><pub-id pub-id-type="pmid">25455030</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovchinnikov</surname><given-names>V</given-names></name><name><surname>Louveau</surname><given-names>JE</given-names></name><name><surname>Barton</surname><given-names>JP</given-names></name><name><surname>Karplus</surname><given-names>M</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies</article-title><source>eLife</source><volume>7</volume><elocation-id>e33038</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33038</pub-id><pub-id pub-id-type="pmid">29442996</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>L</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>Piccoli</surname><given-names>L</given-names></name><name><surname>Kallewaard</surname><given-names>NL</given-names></name><name><surname>Turrini</surname><given-names>F</given-names></name><name><surname>Silacci</surname><given-names>C</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>B</given-names></name><name><surname>Agatic</surname><given-names>G</given-names></name><name><surname>Giacchetto-Sasselli</surname><given-names>I</given-names></name><name><surname>Pellicciotta</surname><given-names>G</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Vicenzi</surname><given-names>E</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapid development of broadly influenza neutralizing antibodies through redundant mutations</article-title><source>Nature</source><volume>516</volume><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/nature13764</pub-id><pub-id pub-id-type="pmid">25296253</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Metzger</surname><given-names>BPH</given-names></name><name><surname>Thornton</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Epistatic drift causes gradual decay of predictability in protein evolution</article-title><source>Science</source><volume>376</volume><fpage>823</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.abn6895</pub-id><pub-id pub-id-type="pmid">35587978</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>UCSF chimerax: structure visualization for researchers, educators, and developers</article-title><source>Protein Science</source><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Ponomarenko</surname><given-names>AI</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>McHugh</surname><given-names>SM</given-names></name><name><surname>Butty</surname><given-names>VL</given-names></name><name><surname>Whittaker</surname><given-names>CA</given-names></name><name><surname>Moore</surname><given-names>CL</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Shoulders</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Destabilized adaptive influenza variants critical for innate immune system escape are potentiated by host chaperones</article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e3000008</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000008</pub-id><pub-id pub-id-type="pmid">30222731</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AM</given-names></name><name><surname>Lawrence</surname><given-names>KR</given-names></name><name><surname>Moulana</surname><given-names>A</given-names></name><name><surname>Dupic</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>MS</given-names></name><name><surname>Cvijovic</surname><given-names>I</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name><name><surname>Desai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies</article-title><source>eLife</source><volume>10</volume><elocation-id>e71393</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.71393</pub-id><pub-id pub-id-type="pmid">34491198</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poelwijk</surname><given-names>FJ</given-names></name><name><surname>Socolich</surname><given-names>M</given-names></name><name><surname>Ranganathan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Learning the pattern of epistasis linking genotype and phenotype in a protein</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4213</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12130-8</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>DD</given-names></name><name><surname>Bajic</surname><given-names>G</given-names></name><name><surname>Ferdman</surname><given-names>J</given-names></name><name><surname>Suphaphiphat</surname><given-names>P</given-names></name><name><surname>Settembre</surname><given-names>EC</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody</article-title><source>PNAS</source><volume>115</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715471115</pub-id><pub-id pub-id-type="pmid">29255041</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachdeva</surname><given-names>V</given-names></name><name><surname>Husain</surname><given-names>K</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Murugan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tuning environmental timescales to evolve and maintain generalists</article-title><source>PNAS</source><volume>117</volume><fpage>12693</fpage><lpage>12699</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914586117</pub-id><pub-id pub-id-type="pmid">32457160</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sailer</surname><given-names>ZR</given-names></name><name><surname>Harms</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High-order epistasis shapes evolutionary trajectories</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005541</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005541</pub-id><pub-id pub-id-type="pmid">28505183</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangesland</surname><given-names>M</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibody focusing to conserved sites of vulnerability: the immunological pathways for “ universal ” influenza vaccines</article-title><source>Vaccines</source><volume>9</volume><elocation-id>125</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020125</pub-id><pub-id pub-id-type="pmid">33562627</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>O’Donnell</surname><given-names>T</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>LR</given-names></name><name><surname>Manischewitz</surname><given-names>J</given-names></name><name><surname>Golding</surname><given-names>H</given-names></name><name><surname>Suphaphiphat</surname><given-names>P</given-names></name><name><surname>Carfi</surname><given-names>A</given-names></name><name><surname>Settembre</surname><given-names>EC</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody</article-title><source>PNAS</source><volume>110</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1073/pnas.1218256109</pub-id><pub-id pub-id-type="pmid">23175789</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Do</surname><given-names>KT</given-names></name><name><surname>McCarthy</surname><given-names>KR</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Immunogenic stimulus for germline precursors of antibodies that engage the influenza hemagglutinin receptor-binding site</article-title><source>Cell Reports</source><volume>13</volume><fpage>2842</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.063</pub-id><pub-id pub-id-type="pmid">26711348</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Therkelsen</surname><given-names>MD</given-names></name><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Viral receptor-binding site antibodies with diverse germline origins</article-title><source>Cell</source><volume>161</volume><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.028</pub-id><pub-id pub-id-type="pmid">25959776</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DJ</given-names></name><name><surname>Lapedes</surname><given-names>AS</given-names></name><name><surname>de Jong</surname><given-names>JC</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Osterhaus</surname><given-names>ADME</given-names></name><name><surname>Fouchier</surname><given-names>RAM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mapping the antigenic and genetic evolution of influenza virus</article-title><source>Science</source><volume>305</volume><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1126/science.1097211</pub-id><pub-id pub-id-type="pmid">15218094</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprenger</surname><given-names>KG</given-names></name><name><surname>Louveau</surname><given-names>JE</given-names></name><name><surname>Murugan</surname><given-names>PM</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Optimizing immunization protocols to elicit broadly neutralizing antibodies</article-title><source>PNAS</source><volume>117</volume><fpage>20077</fpage><lpage>20087</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919329117</pub-id><pub-id pub-id-type="pmid">32747563</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Picton</surname><given-names>LK</given-names></name><name><surname>Thornton</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternative evolutionary histories in the sequence space of an ancient protein</article-title><source>Nature</source><volume>549</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1038/nature23902</pub-id><pub-id pub-id-type="pmid">28902834</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Throsby</surname><given-names>M</given-names></name><name><surname>van den Brink</surname><given-names>E</given-names></name><name><surname>Jongeneelen</surname><given-names>M</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Alard</surname><given-names>P</given-names></name><name><surname>Cornelissen</surname><given-names>L</given-names></name><name><surname>Bakker</surname><given-names>A</given-names></name><name><surname>Cox</surname><given-names>F</given-names></name><name><surname>van Deventer</surname><given-names>E</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>ter Meulen</surname><given-names>J</given-names></name><name><surname>Lasters</surname><given-names>I</given-names></name><name><surname>Carsetti</surname><given-names>R</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>de Kruif</surname><given-names>J</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e3942</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003942</pub-id><pub-id pub-id-type="pmid">19079604</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>JS</given-names></name><name><surname>Zhou</surname><given-names>JQ</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Schmitz</surname><given-names>AJ</given-names></name><name><surname>Rizk</surname><given-names>AA</given-names></name><name><surname>Alsoussi</surname><given-names>WB</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name><name><surname>Amor</surname><given-names>M</given-names></name><name><surname>McIntire</surname><given-names>KM</given-names></name><name><surname>Meade</surname><given-names>P</given-names></name><name><surname>Strohmeier</surname><given-names>S</given-names></name><name><surname>Brent</surname><given-names>RI</given-names></name><name><surname>Richey</surname><given-names>ST</given-names></name><name><surname>Haile</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>YR</given-names></name><name><surname>Klebert</surname><given-names>MK</given-names></name><name><surname>Suessen</surname><given-names>T</given-names></name><name><surname>Teefey</surname><given-names>S</given-names></name><name><surname>Presti</surname><given-names>RM</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Kleinstein</surname><given-names>SH</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human germinal centres engage memory and naive B cells after influenza vaccination</article-title><source>Nature</source><volume>586</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2711-0</pub-id><pub-id pub-id-type="pmid">32866963</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unniraman</surname><given-names>S</given-names></name><name><surname>Schatz</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Strand-biased spreading of mutations during somatic hypermutation</article-title><source>Science</source><volume>317</volume><fpage>1227</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1126/science.1145065</pub-id><pub-id pub-id-type="pmid">17761884</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valley</surname><given-names>CC</given-names></name><name><surname>Cembran</surname><given-names>A</given-names></name><name><surname>Perlmutter</surname><given-names>JD</given-names></name><name><surname>Lewis</surname><given-names>AK</given-names></name><name><surname>Labello</surname><given-names>NP</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Sachs</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The methionine-aromatic motif plays a unique role in stabilizing protein structure</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>34979</fpage><lpage>34991</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.374504</pub-id><pub-id pub-id-type="pmid">22859300</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Deventer</surname><given-names>JA</given-names></name><name><surname>Kelly</surname><given-names>RL</given-names></name><name><surname>Rajan</surname><given-names>S</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name><name><surname>Sidhu</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A switchable yeast display/secretion system</article-title><source>Protein Engineering, Design &amp; Selection</source><volume>28</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1093/protein/gzv043</pub-id><pub-id pub-id-type="pmid">26333274</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Germinal centers</article-title><source>Annual Review of Immunology</source><volume>30</volume><fpage>429</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075032</pub-id><pub-id pub-id-type="pmid">22224772</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Mata-Fink</surname><given-names>J</given-names></name><name><surname>Kriegsman</surname><given-names>B</given-names></name><name><surname>Hanson</surname><given-names>M</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Eisen</surname><given-names>HN</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Wittrup</surname><given-names>KD</given-names></name><name><surname>Kardar</surname><given-names>M</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies</article-title><source>Cell</source><volume>160</volume><fpage>785</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.01.027</pub-id><pub-id pub-id-type="pmid">25662010</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Optimal sequential immunization can focus antibody responses against diversity loss and distraction</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005336</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005336</pub-id><pub-id pub-id-type="pmid">28135270</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreich</surname><given-names>DM</given-names></name><name><surname>Delaney</surname><given-names>NF</given-names></name><name><surname>Depristo</surname><given-names>MA</given-names></name><name><surname>Hartl</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Darwinian evolution can follow only very few mutational paths to fitter proteins</article-title><source>Science</source><volume>312</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1126/science.1123539</pub-id><pub-id pub-id-type="pmid">16601193</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Additivity of mutational effects in proteins</article-title><source>Biochemistry</source><volume>29</volume><fpage>8509</fpage><lpage>8517</lpage><pub-id pub-id-type="doi">10.1021/bi00489a001</pub-id><pub-id pub-id-type="pmid">2271534</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>JRR</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>LR</given-names></name><name><surname>Manischewitz</surname><given-names>J</given-names></name><name><surname>Golding</surname><given-names>H</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Walter</surname><given-names>EB</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin</article-title><source>PNAS</source><volume>108</volume><fpage>14216</fpage><lpage>14221</lpage><pub-id pub-id-type="doi">10.1073/pnas.1111497108</pub-id><pub-id pub-id-type="pmid">21825125</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Grande</surname><given-names>G</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity</article-title><source>Nature Communications</source><volume>8</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/ncomms15371</pub-id><pub-id pub-id-type="pmid">28066851</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Andrews</surname><given-names>SF</given-names></name><name><surname>Raab</surname><given-names>JE</given-names></name><name><surname>O’Connell</surname><given-names>S</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Chambers</surname><given-names>MJ</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Convergent evolution in breadth of two VH6-1-encoded influenza antibody clonotypes from a single donor</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.06.003</pub-id><pub-id pub-id-type="pmid">32619441</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Arlian</surname><given-names>BM</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Yen</surname><given-names>HL</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses</article-title><source>Science</source><volume>368</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1126/science.aaz5143</pub-id><pub-id pub-id-type="pmid">32554590</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>McCauley</surname><given-names>J</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses</article-title><source>Cell Discovery</source><volume>5</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1038/s41421-019-0086-x</pub-id><pub-id pub-id-type="pmid">30993000</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>O’Donnell</surname><given-names>T</given-names></name><name><surname>Therkelsen</surname><given-names>MD</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage</article-title><source>Proteins</source><volume>83</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1002/prot.24745</pub-id><pub-id pub-id-type="pmid">25524709</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>McTamney</surname><given-names>PM</given-names></name><name><surname>Boyington</surname><given-names>JC</given-names></name><name><surname>Ruckwardt</surname><given-names>TJ</given-names></name><name><surname>Crank</surname><given-names>MC</given-names></name><name><surname>Smatti</surname><given-names>MK</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Use of hemagglutinin stem probes demonstrate prevalence of broadly reactive group 1 influenza antibodies in human sera</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>8628</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26538-7</pub-id><pub-id pub-id-type="pmid">29872070</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83628.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.21.508900" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.21.508900"/></front-stub><body><p>In this valuable study, the authors convincingly show that epistasis between mutations plays a role in the evolution of broadly neutralizing influenza antibodies. The authors provided accurate descriptions within the text and included a graphic summary focusing on the epistatic and non-epistatic models.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83628.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.21.508900">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.21.508900v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Hierarchical sequence-affinity landscapes shape the evolution of breadth in an anti-influenza receptor binding site antibody&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Betty Diamond as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>(1) As described in review 1 (recommendation for the authors), some editorial changes are required to make a more accurate description.</p><p>(2) As described in review 2 (recommendation for the authors), a graphic summary, focusing on the epistatic and non-epistatic models, is required.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Line 357: The statement on two of the I-2 mutations (G31D and M34I) is not very convincing. As shown by the unconstrained paths in Figure 5B, the mutation order probabilities of G31D and M34I span quite evenly across most mutation orders under MA90, SI06 as well as the optimal scenario.</p><p>2. It will help readers to follow the flow of the manuscript if the Results section includes subheadings.</p><p>3. Lines 219-220: &quot;(e.g., Y35N, Y48C, D49Y, G31D, Y33H, H35N, N52H)&quot;. It is unclear which chain (heavy or light) these mutations belong to. This issue is present throughout the Results section. Is there a way to specify light chain and heavy chain residues? That will help improve readability.</p><p>4. Lines 267-268: &quot;… we compared the crystal structures of the unbound UCA, I-2, and CH65 as well as CH65 bound to SI06.&quot; It might be a good idea to specify that both UCA and I-2 crystal structures have H35N and Y35N mutations here. It was not mentioned elsewhere until line 963.</p><p>5. Lines 283-286: &quot;Thus, while N52H alone confers affinity to MA90-G189E, G31D and M34I (I-2) reduce the dissociation rate by ~3.5-5 fold to improve affinity (Figure 4C, Figure 4—figure supplement 5). Notably, these interactions are distant from the site of viral escape (G189E, Figure 4B, 4C).&quot; However, based on Figures 4B and 4C, it seems like G31D and N52H are quite close to G189E.</p><p>6. Line 299: &quot;… Y35F mutation upon affinity maturation which is only a removal of a hydroxyl group&quot;. Does Y35F also remove a hydrogen bond between LFWR2 and HCDR3?</p><p>7. Is it possible that the different HCDR3 conformations among UCA (PDB 4HK0), I-2 (PDB 4HK3), CH65 (PDB 4WUK), UCA+Y35N, and I2+Y35N+H35N can be in part explained by the difference in crystal packing since these structures have different space groups?</p><p>8. In Figure 5A and Figure 5 —figure supplement 1, the meanings of &quot;most likely&quot;, &quot;various orders&quot;, and &quot;other orders&quot; need to be clarified in the figure legends.</p><p>9. The specific I-2 mutations (G31D, M34I, N52H) are not mentioned until line 256. It would be nice to have a sentence specifying them when I-2 is first brought up.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The landscapes that the authors show can be presented in schematic views as a graphic summary in supportive figures, focusing on the epistatic mode and non-epistatic mode. This might be helpful for readers to locate the position in the antibody at a glance.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83628.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>(1) As described in review 1 (recommendation for the authors), some editorial changes are required to make a more accurate description.</p></disp-quote><p>These changes have been made and are addressed point-by-point in response to Reviewer #1.</p><disp-quote content-type="editor-comment"><p>(2) As described in review 2 (recommendation for the authors), a graphic summary, focusing on the epistatic and non-epistatic models, is required.</p></disp-quote><p>We have added a graphic summary focusing on the epistatic and non-epistatic models, and present this as Figure 5—figure supplement 3.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Line 357: The statement on two of the I-2 mutations (G31D and M34I) is not very convincing. As shown by the unconstrained paths in Figure 5B, the mutation order probabilities of G31D and M34I span quite evenly across most mutation orders under MA90, SI06 as well as the optimal scenario.</p></disp-quote><p>We agree that the probability of M34I is relatively even up to mutational order ~12. Though G31D is likely to occur up to mutational order ~10, it is amongst the most likely mutations to occur early in maturation (<italic>e.g.,</italic> mutational orders 1-3). We have accordingly modified our description of the data:</p><p>“Even when we do not constrain pathways to pass through I-2, we find that two of the I-2 mutations (G31D and N52H) and the epistatic mutations that interact with HCDR3 (e.g., Y33H, H35N, and previously uncharacterized Y35N) are most likely to occur early in mutational trajectories, especially in scenarios that begin with MA90 selection.”</p><disp-quote content-type="editor-comment"><p>2. It will help readers to follow the flow of the manuscript if the Results section includes subheadings.</p></disp-quote><p>We have added subheadings to the manuscript.</p><disp-quote content-type="editor-comment"><p>3. Lines 219-220: &quot;(e.g., Y35N, Y48C, D49Y, G31D, Y33H, H35N, N52H)&quot;. It is unclear which chain (heavy or light) these mutations belong to. This issue is present throughout the Results section. Is there a way to specify light chain and heavy chain residues? That will help improve readability.</p></disp-quote><p>We have specified what chain each mutation is located in throughout the Results section using V<sub>H</sub> and V<sub>L</sub> notation.</p><disp-quote content-type="editor-comment"><p>4. Lines 267-268: &quot;… we compared the crystal structures of the unbound UCA, I-2, and CH65 as well as CH65 bound to SI06.&quot; It might be a good idea to specify that both UCA and I-2 crystal structures have H35N and Y35N mutations here. It was not mentioned elsewhere until line 963.</p></disp-quote><p>We agree that these lines may be confusing. The crystal structures referenced here are that of the UCA, I-2, and CH65 (without the Y35N and/or H35N mutations in the UCA or I-2). In addition to the previously determined structures, we also determined new structures of the UCA and I-2 with the Y35N and/or H35N mutatons. We've added text to clarify the distinction.</p><disp-quote content-type="editor-comment"><p>5. Lines 283-286: &quot;Thus, while N52H alone confers affinity to MA90-G189E, G31D and M34I (I-2) reduce the dissociation rate by ~3.5-5 fold to improve affinity (Figure 4C, Figure 4—figure supplement 5). Notably, these interactions are distant from the site of viral escape (G189E, Figure 4B, 4C).&quot; However, based on Figures 4B and 4C, it seems like G31D and N52H are quite close to G189E.</p></disp-quote><p>We thank the reviewer for bringing this to our attention. Although the distance between the escape mutation (G189E) and the mutations G31D and N52H is quite large (~15-20Å), this is difficult to infer from the figures. We've accordingly added a new panel to Figure 4C to clearly show this distance between these residues and modified the text to reflect this:</p><p>&quot;Notably, these interactions are distant (~15-20Å) from the residue conferring viral escape, precluding any direct interaction (Figure 4B, 4C).&quot;</p><disp-quote content-type="editor-comment"><p>6. Line 299: &quot;… Y35F mutation upon affinity maturation which is only a removal of a hydroxyl group&quot;. Does Y35F also remove a hydrogen bond between LFWR2 and HCDR3?</p></disp-quote><p>We have clarified the text to reflect that lack of a hydroxyl group in the phenylalanine side chain prohibits hydrogen bonding.</p><disp-quote content-type="editor-comment"><p>7. Is it possible that the different HCDR3 conformations among UCA (PDB 4HK0), I-2 (PDB 4HK3), CH65 (PDB 4WUK), UCA+Y35N, and I2+Y35N+H35N can be in part explained by the difference in crystal packing since these structures have different space groups?</p></disp-quote><p>We thank the reviewer for bringing up this important point. Crystal packing can influence the CDR conformations of unbound Fabs. Indeed, in previously published work, the unbound UCA (4HK0) had two of the copies of the Fab in the asymmetric unit: crystal packing constrained one HCDR3 but the resulted in the other projected into solvent; for the former copy, this resulted in electron density clearly defining the HDCR3, but for the latter it did not. It was inferred that this reflected the inherent disorder of the UCA HCDR3 with many possible conformations. For I-2 (4HK3), crystal packing resulted in the constrained conformation. Here, for UCA+Y35N (8EK6) Fabs have crystal-packing contacts that influence the observed conformation. For I-2+Y35N+H35N Fab, the HCDR3 projects into solvent with no clear electron density suggesting that it can adopt many different conformations. In contrast, the unbound mature antibodies CH65 (4WUK) and CH67 (4HKB) show the same conformation observed in the antigen-bound Fabs: CH65 bound to SI06 HA (5UGY) and CH67 bound to SI06 HA (4HKX). Because the unbound conformations in the non-mature Fabs are influenced by crystal packing (as the reviewer points out), we cannot make any statements about those particular observed conformations, only that the HCDR3s in those Fabs can adopt multiple alternative conformations and are not rigidified as is the case for the affinity-matured antibodies. We've modified text to clarify these points:</p><p>&quot;Previous studies on this lineage<sup>4,54</sup> showed that HCDR3 rigidification contributed to high-affinity binding to SI06: crystal structures of the unbound, affinity-matured Fabs had the same HCDR3 configurations as those in the antigen-bound state; the UCA and I-2, however, were either disordered or constrained, due to crystal packing, in a binding-incompatible state. To determine whether the mutations Y35N and H35N could stabilize a binding-compatible HCDR3 conformation, we determined x-ray crystal structures of unbound Fabs containing Y35N in the UCA background or Y35N and H35N in the I-2 background and compared them to previously determined structures (Figure 4—figure supplement 1C).&quot;</p><disp-quote content-type="editor-comment"><p>8. In Figure 5A and Figure 5 —figure supplement 1, the meanings of &quot;most likely&quot;, &quot;various orders&quot;, and &quot;other orders&quot; need to be clarified in the figure legends.</p></disp-quote><p>We have clarified this in the respective figure legends.</p><disp-quote content-type="editor-comment"><p>9. The specific I-2 mutations (G31D, M34I, N52H) are not mentioned until line 256. It would be nice to have a sentence specifying them when I-2 is first brought up.</p></disp-quote><p>We have specified the I-2 mutations early in the Results section.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The landscapes that the authors show can be presented in schematic views as a graphic summary in supportive figures, focusing on the epistatic mode and non-epistatic mode. This might be helpful for readers to locate the position in the antibody at a glance.</p></disp-quote><p>We have added a graphic summary of the epistatic and non-epistatic models and the corresponding landscapes as Figure 5—figure supplement 3. We have also included a summary of the structural basis of the epistasis in the graphic summary and have also provided a new figure (Figure 3—figure supplement 5) that plots the additive and epistatic effects of mutations on the crystal structure for each antigen.</p></body></sub-article></article>